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Abstract 
A novel coupling reagent for solid phase peptide synthesis has been synthesised under 
optimum conditions and tested for racemisation with all naturally occurring chiral 
amino acids. The coupling reagent has been applied to the total chemical synthesis of 
deglycosylated human erythropoietin (166 residues). The affinity for carbon of the 
N"—protecting group tetrabenzo[a,c,g,i]fluorenyl- 1 7-methoxycarbonyl (Thfinoc) has 
been exploited to simplify the purification of dhEPO and a purification protocol has 
been developed. 
A versatile linker which allows derivatisation at the C-terminus of peptides to either 
the hydrazide or the amide has been synthesised and attachment of the linker to a 
suitable solid support has been investigated. The versatile linker has been used in all 
azide fragment condensation syntheses described herein. 
Investigations have been carried out into enzyme cleavable protecting groups for the 
N8 fimction of lysine. The protecting groups are designed to prevent unambiguous 
coupling during fragment condensation of peptide segments. This methodology has 
been used in the azide condensation of two fragments of Salmon Calcitonin I. In 
addition to this a chemically cleaved protecting group for lysine, developed for use in 
the fragment coupling strategy, has been applied to the azide and active ester (using 
HOCt) coupling of two small fragments of hEPO. 
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Chapter one: Solid Phase Peptide Synthesis 
1. Solid Phase Peptide Synthesis 
1.1 General Introduction 
Advances in the methodology of peptide synthesis have always been stimulated by the 
existence of interesting target molecules. The discovery of naturally occurring, 
biologically active peptides created a surge in synthetic activity throughout the 
1950's, laying the foundation for the modem era of peptide and protein synthesis. 
The improved synthetic capabilities of current peptide and protein research originate 
from a revolutionary development, namely the introduction of the solid phase method 
by Bruce Merrifield', the magnitude of which was recognised by the award of the 
Nobel Prize for Chemistry to Merrifield in 1984.2 
Prior to the solid phase method, the synthesis of peptides in solution was a labourious 
and lengthy process which involved purification and isolation of each intermediate 
compound. Thus, even the assembly of a relatively short peptide sequence required 
highly skilled and experienced chemists. Adopting Menifield's method of chain 
assembly from an insoluble resin, meant that many of the impurities produced during 
peptide synthesis could simply be washed away leaving the peptide bound to the resin. 
Solid phase methods now dominate synthetic peptide research and the principle has 
been extended to other fields such as oligonucleotide synthesis, combinatorial libraries 
and related technologies. For peptide synthesis, Merrifield and others have developed 
his original chemistry to a fine art and today numerous peptides can be synthesised by 
automated solid phase synthesis, owing to the simplicity of its strategy and 
convenience. 
I 
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The basic concept of Solid Phase Peptide Synthesis (SPPS) has been outlined in 
Scheme 1.1 below. 
Side-chain Protecting Group 
0 
N"-Pmtecting gmupM14H4-0H + I Linkerfr—j Supportl 
[Side-chain Rntecting Group 	Attach to 
I 	 linker 
KI 0 
N"-Protecting gro 	 tinker[-1 Support 
Side-chain Pkutecting Gmup Depiotect 
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I II I II ______________ 
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Cleave peptide 
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RO R20 R1 	0 
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Scheme 1.1 Generalised approach to SPPS 
An N" derivatised amino acid is attached to an insoluble support via a linker. The N"-
blocking group is then removed and the next N"-protected amino acid is coupled to 
the free amino function of the first. The deprotection and coupling cycles are 
repeated, washing the resin thoroughly between each cycle, until the desired sequence 
of amino acids is generated. Finally the completed peptide is cleaved from the linker 
and its side-chain protecting groups simultaneously. 
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1.2 Nature of the Polymer Support 
The general requirements for a suitable solid support for SPPS were outlined by 
Merrifield and Erickson in 1976 3  and are set out below. 
The polymer support must: 
have reactive sites at which the peptide can be attached, synthesised and obtained 
in good yield. 
allow good contact between peptide and reagents. 
have properties which allow easy separation from excess reagents and by-
products. 
be stable to the reaction conditions. 
minimise interactions between the growing peptide chains. 
In his original publication' Merrifield used a beaded polystyrene resin containing 
reactive chioromethyl groups. This was prepared by polymerisation of styrene plus 
1% divinylbenzene to produce a rigid cross-linked resin, followed by 
chloromethylation. Effectively this resin contained a percentage of CH 20 groups 
which could be used for substitution of the Cl by the carboxyl group of an a- amino 
acid. Hydrolysis of the ester bond on completion of the peptide sequence could then 
occur via alkyl oxygen fission. 
The small spherical beads of the resin are about 50Rm in diameter but swell to five or 
six times their original volume in organic solvents such as DCM 4, allowing the 
reagents access to the peptide; hence coupling and deprotection can occur within the 
resin and soluble unwanted products can filter through. 
Subsequently, the British scientist Robert Sheppard argued that a resin more 
compatible with the polarity of the growing peptide chain would be more 
3 
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advantageous to solid phase methodology. Accordingly he developed a beaded 
polyamide resin 5,6  with swelling characteristics which are complementary to 
Merrifield's polystyrene resin. The polyamide resins have come into widespread use 
and when supported on kieselguhr are mechanically robust proving suitable for 
continuous flow SPPS. 
1.3 W Protection 
1.3.1 Boc strategy 
A year after his preliminary publication in which Merrifield' established the principles 
of SPS he described a synthesis of bradykinin. 7 The original benzyloxycarbonyl (Z) 
group (1), for N-terminal protection, had been replaced by the more acid labile t-
butoxycarbonyl (Boc) group (2) and Z was now used as a permanent side-chain 
protecting group. 
- o_ o 	 I 	NHR 
(1) 	 (2) 
In this synthesis the C-terminus of the first amino acid residue in the target sequence 
was anchored to the chloromethylpolystyrene resin via its caesium salt displacing 
chloride ion and forming an ester bond. Removal of Boc, from the N  positon, with 
mild acid followed by neutralisation gave the free amino group, to which the second 
amino acid residue was coupled using N,N'-dicyclohexylcarbodihnide (DCC) for 
activation. The peptide chain was lengthened in this way until the desired sequence 
was filly assembled. After cleavage of the peptide from the resin with IlBr/TFA the 
side chains, protected with Z, were deprotected by catalytic hydrogenation to give a 
2 
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quantitative yield of the nonapeptide. At each stage the completely insoluble polymer 
was washed copiously to remove excess reagents and co-products. 
1.3.2 Fmoc strategy 
Over the years, N" protecting group strategy and the linkage of the growing peptide 
chain was studied in detail and as the synthetic targets increased not only in size but in 
sensitivity, the limitations of Boc SPPS became more apparent. Both the repetitive 
cleavage of Boc groups and especially the final cleavage of the peptide from the resin 
involved treatment with strong acids which were clearly destructive to some peptide 
sequences. Thus a fully orthogonal approach to SPPS was developed. The 9-
fluorenylmethyloxycarbonyl (Fmoc), N" protecting group" (3), is very stable towards 
acidic reagents but is cleaved swiftly under certain basic conditions. Piperidine (4) is 
the reagent routinely used and deprotection takes only seconds at room temperature 
via a J3-elimination process (Fig. 1.1). Thus, Fmoc temporary protection can be 





(4) 	 1 
<CH'—NO 	
4 	 CI-12 
(7) 	 ( C 
Fig 1.1 Mechanism of Emoc deprotection 
5 
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The dibenzofiilvene (6) produced from the stabilised clibenzocyclopentadienide anion 
(5) forms the adduct (7) on reaction with excess piperidine (4) and in this way is 
prevented from reacting with the free amine of the peptide. The fhlvene piperidine 
adduct (7) has a strong UV absorbance at 302nni and this property has been used in 
developing a system for monitoring the efficiency of each coupling step in automated 
Fmoc SPPS,' ° the general scheme for which is outlined in Scheme 1.2. 
0 
OXNH.._LC —OH + 
II 
0 
j, Loading  
R1  
LMONrIrOR ~~JBase 
ONHC—OH LhkerH Po 
depmtecdon 
ftNA—O Ho 
Activate and couple 
next ftc-amino add 
Cap any .emaining 




and add cleavage 
LT1GET SEQUENCE 
Scheme 1.2 SPPS utilising Fmoc amino acids 
The initial protected Fmoc-amino acid is first coupled via an ester linkage to the 
exposed hydroxy fimction on the linker in the presence of a catalytic amount of 
DMAP. The resin bound Fmoc-amino acid is base deprotected by treatment with 
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20% piperidinelDMf and, after thorough washing, the second protected amino acid is 
coupled, as either a preactivated species (symmetrical anhydride), or without 
preactivation (in situ) where several different activators may be utilised. A capping 
cycle is then introduced to block any remaining free amino function to prevent its 
participation in subsequent couplings. This sequence of events is repeated until the 
target peptide is obtained. The completed peptide is then released from the acid labile 
linker and the base stable side-chain blocking groups by treatment with acid (usually 
TFA). Each coupling step is monitored by UV as mentioned above. 
Fmoc SPPS and the reagents used will be discussed in detail in the chapters to follow 
along with its applications to peptide synthesis in practice. 
1.4 The Resin Linkage 
1.4.1 Synthesis of C-terminal acids 
The introduction of linkers between the support and the peptide has allowed fine 
tuning of the strength of the peptide-resin bond, so that it can be made more, or less 
labile, to suit the synthetic strategy 
With the advent of Fmoc methodology and the use of t-butyl derived side-chain 
protecting groups came the need for linkers which were more acid labile than the 
conventional polystyrene or Merrifield PAM" resin (8) used in the original Boc 
chemistry. The Wang linker" (9), first introduced for the synthesis of protected 
peptide fragments, is cleaved in mild acid (50% TFA in aprotic solvents) and has 
remained popular in Fmoc SPPS (Fig 1.2). 
In both Boc and Fmoc methodologies the cleavage mechanism is an ester hydrolysis 
by alkyl-oxygen fission. In the case of the p-benzyloxyalcohol (Wang) linker the 
additional p-oxygen donates electrons into the benzyl alcohol ring, stabilising the 
7 
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carbocation formed during the fission process, thus increasing the lability of the 
peptide. 
Roe Strategy: PAM linker 
H NH , - 












Fig 1.2 Acidolytic cleavage of the peptidefrom the linker 
One disadvantage in using the Wang linker is 2,5-diketopiperizine 12 formation with C- 
terminal proline. Utilising the highly acid labile 2-chiorotrityl chloride linker 13,14  (10) 
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(cleaved in 10% acetic acid), this problem can be overcome, diketopiperizine 
formation being suppressed by steric bulk at the C-terminal ester. 
(10) 
More recently linkers, including the clilorotrityl linker, which cleave under extremely 
mild conditions such as dilute TFA 15 (11) and fluoride ion 67 (12) have been 
developed to produce protected peptide fragments for convergent synthesis (Chapter 
4). 
OH 





1.4.2 Synthesis of C-terminal amides and hydrazides 
The use of linkers also allows the functionality at the C-terminus of the peptide to be 
adapted to specific requirements e.g linkers are available for the generation of C-
terminal amides"-' 1-21  and hydrazides' 8 '22 under standard cleavage conditions (Fig 
1.3). 
Synthesis of C-terminal peptide amides is highly desirable as many biologically 
important peptides have a C-terminal amide functionality (Chapter 6) e.g. hormones 
and neurotransmitters and the synthesis of peptide hydrazides is important for 
Ij 
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convergent synthesis using acid andes (Chapter 4). Utilising linkers to derivatise the 
C-terminus allows these C-terminal flinctionalities to be generated using mild 
procedures which are not destructive to the peptide chain. 
cl-to 	MI2 
CH3OL OCH21 	
fr ThA' 5 
(13) 








H2NNI-I 0 	 -KII--KIH 50%ThA/DCM22 
 
R 
R = FimcNR (17) 
060— 	R = BocN}INH (18) DuteTFA16-18 
Fig 1.3 Linkers for the production of C-terminal amides and hydrazides 
10 
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1.5 Activation and Coupling 
The principal reaction in the synthesis of a peptide is acylation of the amino group of 
an amino acid by the carboxyl group of another amino acid to form an amide bond; 
the process is known as coupling. In order to convert carboxylic acids into acylating 
agents their hydroxyl group must be replaced by an electron withdrawing group, X, in 
order to enhance the electrophilicity of the carboxyl group (Fig 1.4). 
o 
RX 	INR 	 it 	NTIR 	w RCHNR 
activated carboxylic 	 peptide bond 
add 
Fig 1.4Acylation of an amino acid: coupling 
Obviously, the success of a peptide synthesis relies mainly upon the ability to couple 
amino acids together efficiently to form the peptide bonds. Accordingly this area has 
attracted much attention and many coupling reagents have been proposed .23  Reagent 
suitability is often ruled by the need to retain the chiral integrity of each amino acid on 
coupling, avoiding racemisation. 
Racemisation of amino acids can occur upon activation of the carboxy function with 
an electron withdrawing substituent, X (19). The mechanism 24 (Fig 1.5) involves the 
formation and enolisation of an oxazolone, (20) and (21), on treatment with base. 
The oxazolones formed are themselves activated carboxylic acid derivatives and 
reaction with an amine can lead to peptide formation. However racemisation via the 
stabilised anion (22) occurs more rapidly than aminolysis and both possible epimers 
(23) and (24) are formed. 
11 
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RLNH 	13- _HX





(24) 	 (21) 
RICONT{ <CONIIR2 
(23) 
Fig 1.5 Base catalysed racemisation of activated amino acids via the oxazolone 
intermediate 
It has been estimated that over 140 methods for peptide bond formation exist 25  but 
only those coupling techniques which have generally been applied to Fmoc SPPS will 
be discussed here. 
1.5.1 Carbodlimides 
Carbodiimides are among some of the most popular activating reagents employed in 
peptide synthesis. N,N'-Dicyclohexylcarbodiimide (DCC) 26 and N,N'-
diispropylcarbodiimide (DIC) 27 (24) are used extensively in SPPS although DIC is 
preferred since the by-product, N,N'-diisopropyl urea (26), formed from the 
amidation reaction (Fig 1.5) is more soluble than its counterpart N,N-
dicyclohexylurea. 
12 
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The carboxy function of the a-amino acid reacts with the carbodiiniide (25) to form 
an 0-acylurea (26), which is a potent acylating reagent. This can then react with the 
free amino fimction of the growing peptide to form a peptide bond, or more usually 
react with another oxygen nucleophile to form either the symmetrical anhydride (28) 
(Section 1. 5.2) or the active ester (29) (Section 1.5.3). 
Although activation via carbodiimides generates an acylating reagent with higher 
reactivity than (28) or (29), this method of activation can cause serious side-reactions 
such as racemisation (Fig 1.4), carboxamide dehydration of asparagine (30) and 















peptide 	 I R2OR H H 	






Fig 1.6 Activation and coupling using the carbodilmide procedure 
13 
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Carboxamide dehydration of aspara&ne 
OH DIC RNH..%rpfcc_< 
o 
RNH 	 RNH 
• OH - 	 0 
H 
N-Acyl urea formation 
/ 
	 / 
- R1N LO 
A (31) 
Fig 1.7 Side reactions caused by MC activation and coupling 
1.5.2 Symmetrical anhydrides 
Symmetrical anhydrides (28) are prepared from reaction of two equivalents of amino 
acid derivative with one equivalent of carbodiimide (25). Although they are normally 
crystalline solids, they are routinely pre-formed automatically during synthesis and are 
used without isolation. 
Aminolysis of symmetrical anhydrides is unambiguous and it has thus found 
widespread use in Fmoc SPPS 28, but the price for this is that only half of the 
expensive Fmoc-amino acid used is incorporated into the product. Mother major 
14 
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drawback to it's use are the side reactions apparent with asparagine, glutamine (Fig 
1.7) and histidine (racemisation). 29 
1.5.3 Active esters 
Although the coupling rates of activated esters are considerably slower than those of 
the symmetrical anhydrides, they have considerable advantages over symmetrical 
anhydrides in that none of the amino acid is 'wasted' and side reactions are minimal. 
Extensive studies have been carried out on the use of Fmoc amino acid active esters 
and these are now routinely used in SPPS. 30 Some important ones are described 
below (Fig 1.8). 
0_4N(CH3)2 1 LJL.N' 
I 	Ii 	'N 
OH 	 2LN' 	PF6 
	
(32) 	 (33) 
0itN(CH3)2] 2 
,~~N iNO 13 	N 
N' 	PF6 	 ' 	 N' 	PF6 
(34) (35) 
Fig 1.8 Coupling reagents used in Fmoc SPPS 
1.5.3.1 IIOBt esters 
i-Hydroxybenzotriazole (HOBt) (32), first introduced into peptide synthesis as an 
additive to the carbodiimide method to prevent racemisation, 3 ' forms an active ester 
which has found great success in Fmoc SPPS. HOBt 32 (36) esters of protected amino 
acids are easily formed for example from DICIHOBt in situ (Fig 1.6). 
15 






HOBt esters can also be formed from either its phosphonium or uronium derivatives 
e.g B0P33 (33), PyBOP34 (34) or TBTU35  (35) (Fig 1.8). 
The phosphonium reagent BOP (33) is an excellent peptide coupling reagent but the 
formation of the carcinogen hexamethyl phosphoric triamide (HMPA) on coupling has 
led to its replacement by PyBOP (34) and more recently, by the uronium salt, TBTU 
(35). These coupling reagents rate as highly as, if not better, than BOP with no 
carcinogenic by-products. 
1.5.3.2 Pentafluorophenyl esters 
Pentafluorophenyl (OPfj) esters36 (37) are also efficient acylating agents and due to 
the bulk of their chemical structures, virtually no side-reactions are observed. They 
react considerably slower than symmetrical anhydrides but the addition of HOBt (32) 
significantly increases the rate of reaction, making these esters very useful activated 





Overall in situ activating reagents have become widely accepted in SPPS because of 
their ease of use, fast reactions and their general lack of side-reactions. 
16 
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2. A Novel Coupling Reagent for Solid Phase Peptide 
Synthesis 
2.1 Introduction 
A recent development in the field of HOBt based coupling reagents has been the 
design of new, improved analogues, 1-hydroxy-7-azabenzotriazole (HOAt) 1 (38) and 





N N 	 H N' 
(38) 	 (39) 
The HOCt analogue which was designed and synythesised, in this laboratory, by 
Amanda Davison 2, originated from a series of N-hydroxy compounds formulated from 






Davison studied a series of imidazoles (X = CR) and triazoles (X = N), of these HOCt 
(39) showed the most promising properties, giving increased acidity compared to 
HOBt, rendering it a better leaving group. Another attractive feature of HOCt was it 
did not absorb at 302nm. This meant that a monitoring system, based upon the 
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Fmoc chromophore could be utilised whereby the efficiency of the acylation reaction 
could be determined prior to Fmoc removal. Thus, if the coupling of an amino acid 
was poor it could easily be recoupled at this stage. This is not possible using the 
monitoring system previously described for Fmoc SPPS (Section 1.3.2) since this is 
based solely on the deprotection of Fmoc after, coupling. 
These promising features encouraged the development of a synthetic route towards 
HOCt. The initial route developed by Davison was based on the literature method of 
Stojonavic. 5 However, there were a number of problems inherent in this synthesis, 
mainly its irreproducibility. 
Jiang3 investigated the synthesis of HOCt further, optimising the individual steps and 
found that the final step could in fact be carried out in water which was a more 
favourable solvent than the absolute ethanol previously used as no rotary evaporation 
was required since the product precipitated from water. In addition the previously 
insoluble Na2CO3 was now completely solubilised. However, it was found that 
replacement of ethanol with water meant a reduction in the yield of HOCt. Thus, 
further work was carried out to try and improve the yield for this step as it was 
preferrable to use water as opposed to ethanol. 
2.2 Synthesis of Ethyl I -hydroxy-1 H-I ,2,3-triazole-4-carboxylate 
It was noted that cycisation of the diazo ester (44), formed in step 4, to HOCt (39) 
(Scheme 2.1) was carried out in acidic conditions. Thus, for the formation of the 
diazo ester, if the pH of the aqueous reaction was acidic, then some HOCt could be 
formed at this stage which, due. to its solubility in water, could be lost on separation 
of the precipitated diazo ester from the water soluble inorganics. This would result in 
a lower overall yield of HOCt. In order to investigate this problem several 
experiments were carried out. The first synthesis was a repeat of Jiang's work in 
order to determine the pH of the aqueous solution in step 4. It was measured as 
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acidic (pH 4.5). Thus, in order to test the above idea step 4 was carried out adjusting 
the pH with 10% Na2CO3 to obtain less acidic conditions. 
HI! 	 0 
Step 1 •6 	 "b' OR + NaNO2 5% H2S0 • HC—C 
HCIH2W 	 OCM/1120 	'oFt 




dry N2 	+ Step 2.7,89 	HC—NMe2 + SOCl2 	 ). HC=NMe2CI 
It 	 O°C-RT. 
0 
 
0 	 H + 	A.R CHCh FIO2C 
Step 3. HC—C" + HC=NMe2CI- 	
-(+ 	
+ FtOCOCH2CI 
11 N2 'OH 	I 	 0°C - FLT 	N2 
(2 equivs) 	4 equiv) 	 (43) 
Ft02C 	H 	 FtO2C 	H 1120,0°C Step 4.5 	
Ni4 	
+ NH2OH 






Scheme 2.1 Synthesis of HOCt 
The results from the experiments are summarised below in Table 1. 
Table 1: pH studies in HOCt synthesis 
21 
Chapter two: A Novel Coupling Reagent for Solid Phase Peptide Synthesis 
The results suggest that the above explanation is true since improved yields of HOCt 
are observed when the diazo ester is formed in less acidic conditions thus preventing 
premature cycisation at this stage. Scheme 2.1 is now the standard protocol for the 
synthesis of HOCt. It is convenient, short (two working days as opposed to one week 
by Davison's method), inexpensive and an average overall yield of 30-35% can be 
achieved reproducibly. 
2.3 Racemisation Studies with HOCt 
Racemisation still remains the most serious side-reaction in peptide synthesis and a 
considerable research effort has been put into this area.' ° Thus, any new coupling 
reagent designed for SPPS should be investigated thoroughly 
In order to study whether HOCt would cause racemisation on amino acid activation, a 
series of tripeptides with the general structure Ma-X-Gly were synthesised (where X 
= amino acid). Histidine was treated as a separate case (Section 2.3. 1) since it is 
known to be problematic. 
Ma-X-Gly was chosen as the model peptide since Gly is not chiral and Ala has a 
characteristic doublet between I and 2 ppm in the 1 H N1\4R corresponding to its side-
chain methyl. Thus, if any of the amino acids should racemise with HOCt a second 
doublet would then be observed for Ma due to the formation of the D isomer (Fig 
2.1) thus providing an easy method of analysis. 
Each tripeptide was synthesised manually in a sonic bath and the amino acids with 
their various side-chain protecting groups were coupled, under standard conditions 
(Chapter 8), as their active HOCt esters. The peptides were analysed using 360 MHz 
'H NIVIIR and the results are summarised below in Table 2. 
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The NMR results obtained for the series of trimers studied showed no evidence of 
racemjsatjon with any of the amino acids listed in Table 2 on activation with HOCt, in 
other words only one doublet was observed between 1 and 2 ppm in the 'H NMR 
spectrum. These results strongly indicate that HOCt does not promote racemisation 
on activation with any of these naturally occurring chiral amino acids. 
Table 2: Racemisation studies with HOCt: using Ala-X-Gly as model 
X Side chain protecting group Racemisation (%) 
Ala N/A 0 
Mg Pmc 0 
Asp t-Bu 0 
Mn Mbh, Trt 0 
Cys Acm, t-Bu, Tn 0 
Gin Tn 0 
Glu t-Bu 0 
lie N/A 0 
Leu N/A 0 
Lys Boc 0 
Met N/A 0 
Phe N/A 0 
Pro N/A 0 
Ser t-Bu 0 
Thr t-Bu 0 
Trp indole NH not protected 0 
Tyr t-Bu 0 
Val N/A 0 
2.3.1 Racemisation studies with Fmoc-llis(Trt) and IEIOCt 
Of all the twenty naturally occuring amino acids, histidine (45) is especially prone to 
racemisation. In addition to the possibility of racemisation via the formation of an 
oxazoloneti (Fig 1.5, Sectionl.5), the side-chain 12  imidazole ring of bistidine can also 
play a part (Fig 2.1). 
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It 	 NK 
_ _ 
K—NH CX 	 • K—NH
4 
C—X 	- K—NB C—X 
(45) 	 (46) 	 (47) 
* = chiral centre 	 D or L configirafion 
Fig 2.1 Effect of imidazole ring on the racemisation of histidine 
The imidazole ring is a weak base but is strong enough to cause intramolecular proton 
abstraction to form (46) which can then form either the D or L amino acid (47). 
Masking the it-nitrogen in the imidazole function would seem to be a worthwhile 
objective, however, the synthesis of it-protected histidine is very difficult and the only 
commercially available analogue is Fmoc-His(Bum)' 3  (48), which is impure and very 
expensive due to its poor yield on synthesis. Fortunately, by introducing a bulky 
protecting group on the i-nitrogen e.g trityl (Trt) (49), the racemisation of histidine 
can be reduced. 
The racemjsation of histidine with HOCt was studied using the model peptide Ala-
His-Gly and the results and reaction conditions are tabulated below (Table 3). 
24 
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0.1%. Fig 2.2 shows two examples of the 360MHz 'H NT%IIR obtained in the 
racemisation studies with histidine illustrating the additional doublet obtained for Ala 
when racemisation occurs. 
A: example of no racemisation with His(Trt) 
B: example of racemisation with His(Tfl) 
Loublets 
ted at 1.15 and 
pm when His 
.ises giving two 
reoisomers. 
Fig 22 Examples of'HNMR obtained for racemisation studies with His. 
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2.4 Conclusions 
The results suggest that not only is racemisation of histidine, when activated with 
HOCt, affected by time but also by temperature. The fact that the amount of 
racemisation is reduced on addition of an excess of HOCt indicates that HOCt, due to 
its acidic nature (pK8 = 2. 1), is protonating the it-nitrogen in the imidazole ring and, in 
doing so, inhibits intramolecular proton abstraction (Fig 2.2). 
The reason for the observed increase in racemisation of histidine, with HOCt 
compared to HOBt, is probably due to DCt being a better leaving group than DBt 
due to its stability. This means the "H is more acidic when histidine is activated with 
HOCt, rendering it extremely labile, thus facilitating racemisation by proton 
abstraction via the imidazole ring (Fig 2.1). 
Prior to these results Fmoc-His(Trt) could not be coupled as the HOCt active ester, 
due to extensive racemisation under standard conditions, and was incorporated onto 
the synthesiser as its HOBt active ester. Now all amino acids can be successfUlly 
incorporated as their active HOCt esters. 
HOCt has been proven to be a superior coupling reagent to HOBt/DIC even when 
double coupling cycles were used for the latter. Thus the synthesis of larger 
polypeptides using HOCt would seem feasible since coupling of amino acids should be 
more efficient, decreasing the possibility of truncated peptides. The following chapter 
discusses the application of HOCt in the synthesis of a 166 amino acid protein with 
reference to other proteins synthesised with this novel coupling reagent. 
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3. Stepwise Solid Phase Synthesis of Deglycosylated 
Human Erythropoietin 
3.1 Introduction 
Erythropoietin (EPO) is the principal hormone involved in the regulation and 
maintenance of red blood cell (erythrocyte) production in the bone marrow. 1,2  The 
hormone is produced in the kidney of the adult and in the liver during foetal life ,3 
production being stimulated under conditions of hypoxia. 4 EPO operates by 
interaction with its receptors on the surface of erythroid precursor cells, in the bone 
marrow, to promote their differentiation into mature erythrocytes. 1,6  However, when 
there is progressive destruction of kidney mass, such as in chronic renal failure, an 
anaemia results due to a decrease in the production of EPO. 7 
In 1977 Miyake et a18 purified EPO to homogeneity from the urine of patients with 
severe aplastic anaemia but, due to the scarcity of material, only limited amino acid 
sequence data was available. This led to the isolation of both cDNA and genomic 
clones of the human EPO (hEPO) gene in 1985." ° Following the cloning and 
expression of the cDNA, it has been possible to isolate recombinant hEPO (rhEPO) 
from chinese hamster ovary (CHO) cells in much larger quantities than was previously 
possible for the naturally occurring hormone. As a result rhEPO has been 
characterised, and is thus valuable for research and is licensed for clinical use. The 
primary sequence of rhEPO consists of 166 amino acids (Fig 3.1) and has a molecular 
mass of 30.4 kDa. It is heavily glycosylated with the oligosaccharide chains 
comprising 40% of the molecular mass, the deglycosylated protein has a molecular 
mass of 18.5 kDa.' 1-13  The protein has N-linked glycosylation sites at asparagines 24, 
38 and 83 and one 0-linked glycosylation site at serine 12612  but it is widely accepted 
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that only the N-linked oligosaccharides are essential for ff11 biological activity in 
vivo 12 ' with the 0-linked oligosaccharide having little influence on either in vivo or 
in vitro bioactivity.' 6" 7 '2° The carbohydrate structures of human and rhEPO have 
been determined .22.21  There are two disulphide bridges in hEPO at cysteines 29-33 
and 7-161 but only the latter has been shown to be essential for its bioactivity.' 2"3 ' 24 
1 	 10 
Ala Pro Pro Arg Leu lie Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu 
20 	 * 	 30 
Glu Ala Lys Glu Ala Giu Asn lie Thr Thr Gly Cys Ala Glu His Cys Ser 
	
* 	40 	 50 
Leu Asn Glu Asm Ile Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Ala Trp 
60 
Lys Arq Met Glu Val Gly Gin Gin Ala Val Glu Val Trp Gin Gly Leu Ala 
70 	 80 	 * 
Leu Leu Ser Giu Ala Val Leu Arg Giy Gin Ala Leu Leu Val Asm Ser Ser 
90 	 100 
Gin Pro Trp Giu Pro Leu Gin Leu His Val Asp Lys Ala Val Ser Gly Leu 
110 
Arg Ser Leu Thr Thr Leu Leu Arg Ala Leu Gly Ala Gin Lys Glu Ala lie 
120 	 * 	 130 
Ser Pro Pro Asp Ala Ala Ser Ala Ala Pro Leu Arg Thr lie Thr Ala Asp 
140 	 150 
Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu 
160 	 166 
Lys Leu Tyr Thr Gly Glu Ala Cys Arg Thr Giy Asp Arg 
* Glycosylation sites: Asn N-linked, Ser 0-linked 
3.1 Amino acid sequence of hEPO showing glycosylation sites 
Imai25 and co-workers have found that CHO-derived hEPO is indistinguishable both 
physiochemically and biologically from urinary hEPO (uEEPO), thus over the last 
decade, the availability of the recombinant hormone has had a dramatic effect on renal 
medicine. As a consequence rhEPO is used routinely in the care of patients with 
chronic kidney failure 26  who are unable to produce sufficient endogenous hEPO. The 
first clinical trials using the recombinant therapeutic agent were initiated in Seattle in 
198527 and in 1986 in London. 28 Subsequently in 1988,29  in the US, only 6 out of 247 
patients failed to respond to rhEPO and, in Seattle, patients who had entered 
maintenance therapy continued to respond to the hormone without developing an 
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immune response . 3°  It would therefore seem that rhEPO is an effective and well 
tolerated drug. 
The major market for rhEPO based therapies is in Japan. This is because brain death 
is not recognised, thus organ donation and hence transplants are very rare. The result 
is a rapidly growing population (10,000 p.a) of patients receiving regular and 
expensive rhEPO dialysis treatment to survive. This situation contrasts with that of 
the UK where kidney transplants are available and the rhEPO market is small in 
comparison. 3 ' 
In addition to its clinical use rhEPO has been the subject of much research concerning 
its structure-fruiction relationships. Both its 3-D structure and those features which 
contribute to its bioactivity through a receptor binding domain remain to be 
elucidated. Various structural models have been proposed 
24,31  (Fig 3.2) which 
postulate a substantial a-helical content with a structural motif shared by related 
molecules such as growth hormone and prolactin. It has been suggested that these 
molecules constitute a helical cytokine superfamily with common ancestral 
origin. 24 
Loop 8C 
Fig 3.2 Postulated structural model for hEPO; a ribbon diagram of the predicted 
EPO tertiary structure. The four a-helices are labelled A-D 
31 
Chapter three: Stepwise Solid Phase Synthesis of Erythropoietin 
3.2 The Aims 
Due to the interest in larger synthetic targets it was the aim of the research to 
synthesise a protein >150 amino acids in order to test HOCt as a coupling reagent and 
other methodology developed in this laboratory for the synthesis of large 
polypeptides. Proteins in this size range have previously been unattainable by other 
methodologies with the only total chemical synthesis of a polypeptide of this size (140 
a.a) reported by Kent in 1986 33  who synthesised Jnterleukin-3 utilising Boc SPPS and 
double coupling each amino acid via the symmetrical anhydride (Section 1.1.5.2). 
Standard coupling with HOCt requires only single couple cycles and no amino acid is 
effectively 'wasted'. hEPO was chosen as a model as it is a biologically important 
protein with therapeutic value and was within the limits of the target size. 
It was hoped that, if the synthesis and purification of deglycosylated hEPO (dhEPO) 
were successful this would lead to its crystallisation, NMR structural data and 
ultimately the synthesis of a glycosylated form of hEPO or similar with biological 
activity. 
The advantages of producing such a protein chemically are outlined below: 
Guaranteed homogeneous product with the correct sequence of amino acids 
(such guarantees cannot always be met by recombinant means due to DNA 
mismatching). 
Protein structure can be modified easily for structure thnction studies using 
chemical means (recombinant techniques using site directed mutagenesis are 
essentially limited to the twenty natural amino acids. In addition these methods 
are not always adequate due to their time consuming nature and the fact that 
expression and purification of the altered product is not always straightforward). 
NMit probe nuclei can be incorporated at any predetermined single atom site in 
the protein to aid 3-D structure determination. 
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Novel improved forms of the hormone could be synthesised via chemical 
glycosylation with suitable oligosaccharides to give enhanced therapeutic value. 
N-linked glycosylation plays a key role in in vivo protein activity, thus it is 
possible to mimic the naturally occurring glycosylation pattern to discover 
whether any of the glycoforms are more active than others. 
3.3 Chemical Synthesis of Deglycosylated Human Erythropoietin 
To synthesise and purify a protein of this size would be a challenge for any chemist 
and initially there was no guarantee that the methodology could stretch to such limits. 
Therefore it was not surprising that the synthesis had to be repeated several times to 
obtain more protein. This was due to loss of material during the purification and not 
because the synthesis had been unsuccessful. In fact the synthesis proceeded 
extremely well, considering the number of chemical steps involved. 
The graph below shows the deprotection profile of the optimised synthesis for 








1 10 19 28 37 46 55 64 73 82 91 im iCe 118 127 136 145 154 163 
RESIDUE 
Graph]: Deprotection profile for dhEPO 
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Assembly of the dhEPO sequence (Fig 3.1) was carried out on a 0. lmmol scale using 
Fmoc-Arg(Pmc) thnctionalised Wang resin and an ABI 430A peptide synthesiser. 
The amino acids were single coupled as their active HOCt esters with the exception of 
the last 20 residues which were double coupled. Preliminary results indicated that 
double coupling from Lys 20 to Ala I may improve on yield since the majority of the 
impurities had a molecular mass of approximately 16 kDa as estimated by SDS 
PAGE. 
The deprotection profile shows coupling percentages of greater than 100% which is 
possibly due to difficulties with resin swelling. The profile was therefore treated only 
as an indication that the synthesis had not 'crashed' and that there were no significant 
'drops' in the coupling efficiency. Overall the synthesis proceeded extremely well and 
a final coupling of 56% is very promising for a molecule of this size when compared 
to other syntheses of smaller polypeptides in the laboratory. An amino acid analysis 
was carried out at this stage on a few milligrams of the resin bound protein (Table 4) 
to confirm the success of the synthesis. 
Table 4 A.A.A of resin bound dI,EPO (SO) 
Amino acid Found Expected 
Asx 12.7 12 
Thr 10.4 11 
Ser 8.07 10 
Clx 20.1 19 
Pro 9.4 8 
Gly 11.5 9 
Ala 20.3 19 
Cys 16 4 
Val 10.4 11 
Met 0.97 1 
Ile 3.7 5 
Lea 21.7 23 
Tyr 4.4 4 
Phe 3.83 4 
His 1,8 2 
Lys 8.71 8 
Mg 12.92 13 
Tp n.d 3 
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The values obtained from the amino acid analysis were in good agreement with the 
expected composition, thus with the knowlege that the synthesis had been successful a 
purification protocol was developed. 
The following discussion will mainly concentrate on protein obtained from the 
optimised synthesis and the final purification protocol adopted, although difficulties 
encountered in the development of this from preliminary syntheses will be mentioned. 
3,4 Purification of Deglycosylated Human Erythropoietin 
Although the synthesis of dhEPO was initially considered the most difficult stage due 
to its uncertainty, the main obstacle to the success of the synthesis lay in the 
subsequent purification. In fact it was expected that the crude product may largely be 
composed of impurities due to either side-reactions occurring during assembly and 
cleavage 34,  or due to incomplete coupling steps forming truncated peptides (N-
terminal acetylated peptides formed on capping). Separation of the target protein 
from the truncated sequences can be labour intensive, sometimes even impossible due 
to the physical and chemical similarities between the desired sequence and the shorter 
truncated impurities. This can often require protracted purification in order to isolate 
the target protein in pure form, 15  and this in turn can result in a low yield of the 
isolated product. 
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Recently, several methods have been reported which allow differentiation between the 
target sequence and any acetylated truncations. The free N-terminus of the resin 
bound polypeptide is derivatised with a group, which then allows separation of the 
desired sequence from the acetylated truncations either by affinity type binding 36 '37 or 
covalent attachment 38 to a solid support. Ramage et al have developed a base labile 
N"-protecting group, tetrabenzo[a, c,g, i]fluorenyl- I 7-methoxycarbonyl (Thflnoc) 
(51), for both affinity purification of polypeptides on porous graphitised carbon 
(PGC)39 '40 and also as a hydrophobic chromatographic probe to simplify the 
purification of peptides by RP-FIPLC or gel filtration . 4(' Thfinoc methodology has 
been applied to the purification of the chemically synthesised dIIEPO (50) using 
denaturing conditions. The principles involved in this method are outlined below in 
Scheme 3.1. 
(a1971-FIPLC or 
SIDE CHAIN PROTECTIONI 	 filtration 
Thfli)c—NH—PEPTIDE--E]--fResin ifA 	Thflmc—NH—PEPTIDE—OH (b) diaJ3S 
Scavengers 
t TRUNCATED PEPTIDES 	 ± TRUNCATED PEPTIDES 
(c) Affinity purification 
on carbon 
CIfb A t. wash out tnmcations 	R 	NH_PEPE_OH 2. 2O%pierithne in B I6MGdm.Cl:isopropanol(l:1) 0 N 
Scheme 3.1 Tbfmocpurjflcation 
On completion of the synthesis the resin bound product (50) was sonicated in the 
presence of acetic anhydride/HOBtIDIEA in DCM in order to cap any remaining free 
amino groups. The N-terminal Fmoc group was then removed and after thoroughly 
washing the resin, Thfinoc was introduced by treatment with the chloroformate (5 1) 
and DIEA in DCM. The resin bound Thflnoc labelled cIhEPO (52) was thoroughly 
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washed with DCM and dried to afford 2g of resin bound Thfinoc-dhEPO. A trial 
cleavage was carried out on a portion of the resin bound material in order to optimise 
the time required for cleavage. This was achieved by acidolytic cleavage using a 
scavenger cocktail containing EDT, thioanisole, water and phenol. Samples of the 
cleavage mixture were analysed after 3h and every hour afterwards until a total of 6h 
had passed. HPLC analysis indicated that the optimum time for cleavage was 
approximately 4.5h since no significant change was observed in the HPLC profile 
after this time. More importantly it was considered that subjecting the protein to TFA 
for longer than this may cause shearing of the chain although this was not proven at 
this stage. 
A large scale cleavage was carried out using the remaining 2g of resin. The crude 
Thffiioc-labelled protein was isolated, after removal of the resin by filtration followed 
by rapid concentration of the filtrate in vacua, ether precipitation and lyophilisation 
affording 9 14mg of crude Thflnoc-dhEPO (53). Amino acid analysis was performed 
on the crude material over a range of hydrolysis times in order to optimise the time 
required for breakdown of the protein into its consecutive amino acids. The results 
are summarised in Table 5 below. The results indicate that the optimum time required 
for complete hydrolysis was approximately 48h (highlighted in bold) as these values 
gave the best comparison with the expected composition. 
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Table 5: A.A.A of crude Tbf,noc-dhEPO (53) at various hydrolysis times 
Found; Hydrolysis time (hours)  
Amino acid 24 36 48 60 72 Expected 
Asx 11.6 11.3 12.7 10.3 8.3 12 
Thr 12.5 10.6 11.2 11.1 10.3 11 
Set 11 10.8 10.7 6.0 9.8 10 
GIx 18.0 18.2 18.8 17.0 15.0 19 
Pro 6.3 5.3 7.3 5.1 6.0 8 
Gly 11.0 11.3 13.5 9.0 10.3 9 
Ala 18.4 17.6 20.1 16.3 15.0 19 
Cys 5.3 2.26 3.9 2.9 3.2 4 
Val 8.2 9.5 10.6 10.0 7.12 11 
Met 0.55 0.57 1.0 1.0 1.96 1 
Ile 5.1 5.0 5.0 5.0 5.2 5 
Leu 24.7 21.7 22.5 19.7 15.7 23 
Tyr 3.9 4.2 4.8 2.4 4.0 4 
Phe 3.25 3.53 4.1 1.7 3.2 4 
His 1.04 1.2 1.5 1.13 2.7 2 
Lys 8.8 8 8.8 11,8  8 
Mg 11.97 13.0 12.9 10.2 9.1 13 
Tip n.d n.d n.d n.d n.d 3 
As outlined in Scheme 3.1 three options were now available for the first stages of the 
purification of d1IEPO with Thfinoc and are as follows: 
Purification by HPLC or gel filtration using Thfinoc as a hydrophobic 
chromatographic probe (UV absorbance at 364nm). 
Dialysis 
Affinity purification using carbon 
In the early stages of the research method (c) was not employed due to the fact that 
removal of the protein from the carbon bound Thfinoc group involved strongly basic 
conditions (10% piperidine) which had previously been shown to result in the 
formation of polymeric aggregates in the presence of free thiol groups 41 ' 42 (dkEPO has 
four). Deprotection using either route (a) or (b) can be accomplished at pH 8 where 
any thiols can be maintained in the reduced state by the addition of Clellands reagent 
(DTT)41 . This method of deprotection cannot be applied when utilising affinity 
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purification as it takes several hours and this would be too long to leave the protein 
bound to carbon. 
Method (a) was chosen at first but attempts at purification by both HPLC and gel 
filtration failed. 
The combination of a very hydrophobic protein (Fig 3.3) with a hydrophobic probe 
resulted in the majority of the tagged protein sticking to the HPLC column; thus 
virtually no protein was recovered. HPLC was therefore used for analysis purposes 
only. 
Gel filration using Sephadex 0-50 monitoring at 226 and 365nm seemed promising at 
first as some separation was observed but all fractions showed an absorbance at 
365nm, indicating the presence of Thfinoc which, in theory, should only have bound 
to the dhEPO. Analysis by BPLC of the fractions collected gave identical traces for 
all, thus there was no resolution and the protein was merely eluting at different stages 
depending on how it had bound to the gel. 
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Dialysis of the tagged protein using a molecular weight cut off (MWCO) of 10,000 
cleaned the protein to a certain extent but the procedure took several weeks and 
consumed litres of solvent due to the number of times the solution had to be changed. 
Following these results it was proposed that an attempt to purify the material by 
method (c) should be made. It was suggested that by acidifying the piperidine mixture 
to pH 8 with addition of DTT immediately after fast release of the protein from 
Thfinoc on carbon would prevent polymerisation via the cysteine side-chains, if this 
was successftul not only would it be less time consuming than dialysis but most 
importantly it would show that the methodology was appropriate for large 
hydrophobic polyp eptides containing cysteine residues. 
The method was carried out first of all using material from the preliminary syntheses 
and PGC was used as the adsorption medium. The purification step went extremely 
well and no polymerisation was observed. Owing to the success of this, the method 
was applied to material from the optimised synthesis but PGC was replaced by much 
cheaper charcoal as the adsorption medium. 
Prior to adsorption, the charcoal had to be washed thoroughly with the solvents used 
for the method (10% piperidine/6MGdm.Cl:isopropanol (1:1) (A) and 
6MGdntCl:isopropanol (1:1) (B)). It is advisable to wash with (A) first then wash 
copiously with (B) as any trace of piperidine will cause cleavage of Thfinoc from the 
protein on adsorption. 
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Abs = 364nm and 214nm correspon 
Thfinoc-dhEPO. 
L= 12mins, 60%B, 13mins, 62% 
Rt (minutes) 	 20 
Fig. 3.4 HPLC trace showing crude Tbfmoc-dhEPO (53) 
The crude Thfinoc tagged protein (53) (Fig 3.4) was dissolved in (B) and added to 
the freshly washed charcoal. Adsorption of Thfluioc-dhEPO onto charcoal was 
monitored by HPLC (UV set at 364nm) and was assumed to be complete after 30 
minutes as a flat baseline was observed. The charcoal was then washed with (B) and 
washing was continued until no absorbance was observed by HPLC (UV set at 
214nm). Experiments have shown that vortexing the mixture, centrifuging the carbon 
to a pellet then discarding the supernatant is much more effective than using a carbon 
column. Once the truncated peptides had been removed the protein was released 
from Thflnoc by vortexing the charcoal mixture in (A) for 15 minutes then repeating 
and finally washing with (B). (B) was combined with (A) and the solution was 
reduced in vacuo to remove isopropanol. The pH of the protein solution was 
adjusted to 8 and incubated at 37°C after addition of DTT to reduce the cysteine side-
chains. Again the purification proceeded well with no polymerisation and a single 
broad peak with only a few shoulders on its side was observed on FIPLC analysis (Fig 
3.5) of the Ththioc purified protein (54). The shoulders apparent on the side of the 
main peak suggest the presence of some remaining impurities but this was to be 
expected considering the size of the protein. 
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Abs = 214nm 
= 12mins, 60%BA 
0 	 R (minutes) 	 20 
Fig. 3.5 HPLC trace showing Tbfmocpurjfled dhEPO (54) 
The impurities could be either high molecular weight truncated material which has not 
been removed on washing, perhaps due to binding of the aromatic side-chains to the 
charcoal or the protein has sheared during cleavage with TFA creating non-acetylated 
truncations which can then couple to Thfinoc during loading and thus be carried 
through in the purification or, most likely, the impurities are deletion peptides. 
Deletions are similar to truncated peptides but, unlike truncations, are not acetylated 
during the capping step. This can happen if the growing peptide chain in some way 
inhibits the resin from swelling to its fill potential, thus preventing all free amino 
functions from being exposed to the acetic anhydride used for capping. However, 
these sites can become available for coupling later in the synthesis, again due to a 
change in swelling properties of the peptide-resin. Thus, as well as incorporating 
Thfinoc onto the target sequence, the deletion sequences can also become labelled. 
3.4.2 FPLC purification of dhEPO by gel filtration (55) 
In order to separate the remaining impurities from the desired protein FPLC gel 
filtration was applied, adopting the principle of size exclusion (largest molecular 
weight elutes first). The column was calibrated with known molecular weight 
standards (Ribonuclease A, MWt 13,700 and Chymotripsinogen A, MWt 25,000) 
prior to purification to ensure the protein synthesised was of the correct molecular 
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weight since techniques such as mass spectrometry (MS) and SDS PAGE had proven 
unsuccessful so far. The protein was injected onto the size exclusion column 
(Superdex 75) and eluted with 6M GdniCl. The procedure followed for MWt 
determination is described below. 
3.4.2.1 Molecular weight determination of dhEPO from F.PLC 
The technique assumes the same relationship between molecular size and molecular 
weight for all proteins. A graph can be constructed by plotting the elution volume 
parameter (kAy) of the standards versus the logarithm of their molecular weight. 




where ye = elution volume, Vo = column void volume and Vt = column bed volume. 
Thus, the MWt of the protein synthesised can be determined by calculating its kAy 











I 	 Chymotrypsinogen A 
1 MWt=25,000 
I 	 I 	• 	I 	 I 	• 	I 	• 	I 
4.15 4.20 4.25 4.30 4.35 4.40 
log MWL 
Graph 2 Plot of logMWt vs kA vto determine MElt of dhEPO fractions eluting from 
FPLC using two known MWt standards 
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From the graph the log MWt calculated for dJiEPO is 4.2625 which compares well 
with the expected value of 4.2647. Thus, this is a good indication that the protein 
synthesised is dhEPO as it is eluting from FPLC at the correct molecular weight with 
respect to the standards. 
Abs = 214nm 
12 mins, 60%B 
0 	 Rt (minutes) 	 20 
Fig. 3.6 HPLC trace showing FPLC gel filtered dhEPO (55) 
The fractions collected were analysed by HPLC and this showed a single broad peak 
(Fig 3.6) (55) with no shoulders for the resolved protein. Fractions producing 
identical traces were pooled and concentrated to a small volume. Any unresolved 
material was recombined, concentrated and reapplied to the column in order to 
maximise recovery. Protein content was determined by UV analysis 43 to give an 
approximate yield of 12.6mg of purified protein. 
3.5 Characterisation of Purified dhEPO (55) 
Amino acid analysis data (Table 6) was obtained for the purified protein and, as 
before, the found composition was in good agreement with the expected composition. 
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Table 6A.A.A ofFPLCpurified dhEPO (55) 
Amino acid Found Expected 
Asx 12.3 12 
Thr 10.2 11 
Ser 8.5 10 
GIx 20.5 19 
Pro 8.3 8 
Gly 10.4 9 
Ala 19.2 19 
Cys 0.1 4 
Val 12.2 11 
Met 1.2 1 
Ile 4.4 5 
Leu 22.0 23 
Tyr 4.6 4 
Phe 4.1 4 
His 2.7 2 
Lys 8.7 8 
Arg 12.9 13 
Trp n.d 3 
Although the amino acid analysis data and the molecular weight determination from 
FPLC are very encouraging and a good indication that the correct material has been 
synthesised, more substantial evidence was required. 
3.5.1 Tryptic digest and mass spectrometry data 
It has been mentioned previously that MS analysis using MALDI TOF MS failed for 
the intact protein. However, it was thought that on hydrolysing the protein into 
smaller fragments using a proteolytic enzyme, MS data could be obtained for these 
smaller peptides. 
Trypsin was the enzyme of choice as it has only two cleavage sites (cuts at the C-
terminus of Lys and Arg) which would minimise the number of fragments obtained 
and, due to its robust nature, should be able to withstand the 3M Gdm.Cl solution 
used (it was found that dialysis of the protein into low salt, unless the protein solution 
was very dilute, resulted in its precipitation). 
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Protein digestion followed by MS analysis of the mixture showed evidence for five 
main sites of cleavage thus the 3M GdmCl solution had caused some enzyme 
inhibition as not all possible cuts were observed. However, this was considered an 
advantage as the molecular mass of some of the predicted fragments would have been 
too small to detect by MALDI TOF MS. The results are tabulated below. 
Table 7MS data obtainedfroni tryptic digest 
Fragment 
Mass 
Found 	 Expected 
5-54 5754.49 (TFA salt) 5655.80 
46-97 5967.87 (C salt) 5931.12 
59-103 5478.36 (Nat salt) 5453.30 
98-140 4435.25 4435.48 
111-150 3810.34(H20) 3795.03 
From the results obtained there was no evidence for the N-terminal amino acids (1-4) 
and it was important to know that the synthesis had proceeded to the end in order to 
confirm that this was not simply a deletion sequence which had been purified, thus 
other methods had to be employed to analyse this portion. 
3.5.2 Sequencing analysis 44 
The intact protein was then sequenced (Welhnet) from the N-terminus TM in an attempt 
to characterise this part of dhEPO. This was performed by Edman degradation 
(Scheme 3.2), labelling the N-terminus with phenyl isothiocyanate (55)•45 
Phenyl isothiocyanate (PTH) (56) is attached to the free N-terminus of the purified 
protein. The labelled amino terminal residue (PTH-Ala) (57) can then be released 
without hydrolysing the rest of the protein. Hence the amino-terminal 'residue of the 
shortened protein (dhEPO 2-166) can be determined in the second round. 
A total of 19 rounds of Edman degradation were performed satisfactorily on the 
purified dhEPO confirming the N-terminal region. It was not possible to sequence 
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further due to the size of the protein. However combining these results with MS 
analysis from the tryptic digest and amino acid analysis stongly indicates that the 
correct material had been synthesised. 
N'ICX
5 	 166 
	
+ 	H2N—C—C—Pro—Pro—Arg—Leu—llo-- -------- —Arg—OH 












s 	 Release H 	I 
5 	 166 yLCH3 112N—Pro—Pro—Arg—Leu—lle— -------- —Arg--OH 
0 	 Protein shortened by one residue 
PM-Ala 
(57) 
Scheme 3.2 Process of Edman degradation using phenyl isothiocyanate 
3.5.3 SDS PAGE 46  and western blot analysis 47 '48 
It was stated previously that SDS PAGE had been very unsuccessful for dliEPO due 
to either no band observed on staining or if a band was visible it was badly streaked. 
Mainly through trial and error gels have been obtained for the purified material and 
are shown in Fig 3.7 below. 
MWt 
- standards .-- 	 -- 
- 94.000 - 
67,000 
Purified dhEPO 






Gel  Gel  
Fig 3.7 SDS gels of (55) performed on 16% (A) and 20% acrylamide (B) 
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Gel A was performed on 20% acrylamide and B was performed on 16% acrylamide 
using the method of Laemmli . 46 As can be seen there is still significant smearing but 
the band is within the correct molecular weight and this has also been confirmed by 
Western blotting analysis. 
A monoclonal mouse anti-hEPO antibody (AE7A5, Genzyme diagnostics, West 
Mailing, UK) exists and is specific for the first 26 residues of hEPO. Western 
blotting4748 using this antibody was carried out on the purified dhEPO and also on 
samples from each stage of the purification protocol (Fig.3.8). The bands obtained 
were compared with a set of molecular weight markers (New England Biolabs) and a 









Fig 3.8 Western blot analysis of (53), (54), (55), (58) on PUlP membrane; all 
rmples contained protein of mass —I8kDa to which the anti-EPO antibody binds 
The gel shows that the antibody was active for all samples and the bands for each 
sample are within the correct molecular weight for dhEPO ('-18.5kDa) 
3.6 Oxidation and Refolding 
The normal biologically active form of a protein is the folded state which is the 
thermodynamically preferred conformation for the protein. This thermodynamically 
stable three dimensional structure is maintained by relatively weak interatomic forces 
such as hydrogen bonding, hydrophobic interaction and ionic interaction. 49  Covalent 
bonds between the sulphur atoms on the cysteine side-chains form intramolecular 
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disulphide bridges in the polypeptide chain (or in some cases intermolecular disulphide 
bridges are formed between separate polypeptide chains). These disulphide 
connections must be formed in the correct way in order to give rise to the desired 
biological activity. 
Generation of disulphide bonds can often be hindered by practical difficulties such as 
instability or insolubility of the reduced form, the latter was evident during the 
refolding of dhEPO which has four cysteine residues. It was found that very dilute 
solutions (1mg in 11) were required to avoid precipitation of the protein when 
dialysing from the high salt concentrations (6M Gdm.Cl) required for denaturing into 
the very low salt concentrations (50mM Tris.HC1) required for folding. 
Protein folding was accomplished by using a literature method developed for 
deglycosylated rhEPO. 24 The fully reduced denatured dJIEPO was slowly dialysed 
against copper sulphate (40j.tM) in Tris.HC1 buffer at pH 8, 5°C. Folding was 
monitored by HPLC and was considered complete when a sharp peak was observed in 
place of the broad hump for the reduced, denatured material (Fig. 3.9). This is usually 
a good indication that folding has occurred but in order to prove that this was folded 
protein, a sample was removed from dialysis, denatured and as expected the 
beautifully sharp peak collapsed to a broad hump corresponding to the denatured 
protein. 
Abs = 214nm 
R = 12,60%B 
0 	 Rt (minutes) 	 20 
Fig 3.8 HPLC trace of (58) 
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An attempt has been made to obtain structural analysis on the folded dhEPO (58) but 
problems were encountered when trying to concentrate the protein into a small 
enough volume for this. It was found that the protein stuck to the membranes used 
during concentration and material was lost due to this. dhEPO is known to be a very 
sticky protein and extremely difficult to handle. Despite this a sample was eventually 
obtained by using a vaccuum centrifuge to concentrate the solution. However, it was 
very difficult to acquire an accurate estimate, by UV, of the quantity of protein 
present and CD analysis does require accurate protein concentrations to determine 
helical and 13-sheet content, thus it was not surprising that the analysis was 
unsuccessful. Other explanations are possible. 
It could be that the protein is unstable unless maintained in very dilute solution, as it 
has been noted that the commercially available protein is not supplied as an isolated 
product, but as a dilute solution (2.5.tgiwl). Furthermore, in the plasma hEPO has a 
concentration of 0. 1tg/L (range 0.5-2.5j.tgIL). In addition to this, the synthetic 
material lacks the oligosaccharide side-chains which have been recognised to be 
important for the stability of glycoproteins. 50 Moreover hEPO is known to have a 
very short half life of 7.5h (range 4-12h). 
As well as structural analysis it is also important that biological testing should be 
carried out; even though it is known that the deglycosylated protein does not have in 
vivo activity it does have compatible in vitro activity. Unfortunately the success rate 
in finding a group to set up the required assay has been poor. Thus the research has 
been stalled for the time being. 
3.7 Future Research 
Obviously much more work is required in this area as the main objective is to obtain 
structural analysis (crystallography, NMR etc) on dhEPO. To do this the protein 
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must be synthesised again, and a new purification protocol from that adopted here 
may have to be developed in order to obtain a good sample of the protein. 
For instance it has been shown that the biological activity of hEPO can be severely 
reduced if the protein is stored in 6M Gdm.C1 for long periods of time. 51 If the 
biological activity is affected, then it would be reasonable to assume that this is 
harmful to the protein structure in general. It would therefore be advantageous not to 
use FPLC as this would minimise the length of time the protein is in 6M Gdni.Cl (a 
few hours as opposed to several weeks). Also chromatography can result in loss of 
valuable material due to irreversible binding of the protein to the fimctional groups in 
the column medium. The modified protocol is outlined below. 
Attachment of Tbfmoc 
Cleavage from resin 
Purification by Ammonium Sulphate 
Precipitation 
FTbfmoc Purification 
Denaturing and Folding 
hEPOI 
Scheme 3.3 New purification protocol proposed for synthetic dhEPO 
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This new protocol (Scheme 3.3) still employs Thflnoc purification as it proved to be 
an excellent method of purification and, although it is essentially a chromatographic 
technique, recovery from charcoal was almost quantitative. Thfinoc would now be 
the final step in the purification and would follow precipitation. Precipitation is the 
purification technique commonly applied by biologists when purifying recombinant 
proteins. It works on the principal that different polypeptides will precipitate from 
solution at different salt concentrations (ammonium sulphate is normally used). 
Utilising Thflnoc would also provide a means for easy identification of the target 
protein by UV during precipitation, and its hydrophobic and bulky nature, should also 
facilitate this procedure. Immediately reducing the protein after Thfinoc purification 
then folding, should produce pure dhEPO ready for crystallisation. If successful in 
this it would then be of interest to produce a glycoform of the protein. 
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4. Convergent Synthesis 
4.1 Introduction 
The stepwise synthesis of hEPO (chapter 3) and other biologically important 
proteins' - ' o has demonstrated the scope and utility of stepwise SPPS. These synthetic 
protocols, however, cannot always be extended to the assembly of large polypeptides 
due to problems with aggregation and interaction of the growing peptide chain with 
the resin which is sequence dependant." This is demonstrated by the surprisingly 
small number of successful protein syntheses reported in the literature, and by the 
large number of ambiguous syntheses typically yielding poorly characterised 
products. 2 
An alternative approach to the stepwise construction of long peptide chains is to 
adopt a convergent strategy in which smaller peptide segments of the protein are 
individually synthesised and linked together to produce the desired sequence. In 
principle, convergent synthesis has the advantage that small peptide fragments are 
straightforward to synthesise and purify, thus giving increased yields. More 
importantly, the difference in size between product and reactants should allow easy 
purification of the target molecule. 
The main problem with this strategy is ensuring selectivity of the coupling reaction. 
Thus, the original convergent strategy involved coupling of maximally protected 
fragments via the active ester. However, the low solubility of large protected peptide 
fragments in organic solvents has meant that few laboratories have used this approach 
successfully. 
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4.2 Coupling of Minimally Protected Peptide Fragments 
In order to overcome the solubility problems encountered with maximally protected 
peptide fragments, chemical coupling of minimally protected peptide segments has 
been explored by some groups. 13-17 
4.2.1 Chemical Ligation 
In 1992 Scholzner and Kent 13  reported the synthesis of a fully biologically active 
analogue of HIV-1 protease containing a thioester pseudo-peptide bond at the ligation 
site (51 Gly-52Gly). The N-terminal fragment contained a thioacid function whilst the 
C-terminus incorporated a bromo acetyl function. The two segments were ligated 
with no side-chain protection, even on cysteine residues. 
A further variation of this work was reported in 1994 for the synthesis of IL-S' 4 (Fig 
4.1) (62). The ligation reaction this time involved nucleophilic attack by the thiol 
group of an N-terminal cysteine residue on one fragment (60), with the C-terminus of 
the other fragment which was flinctionalised with a thioester (59). Displacement of 
the thioester formed the intermediate (61) which then spontaneously rearranged to 
give the natural amide bond of the product protein (62) and regenerated the thiol of 
the cysteine residue; again no side-chain protection was required. 
More recently the chemically robust thioether linkage has been introduced into the 
field as a more generally applicable approach to chemical ligation. This again was 
applied to the synthesis of HIV- 1 protease. 15 
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H3Nt_17.33 C0S_CH2_f 	+ 	NH3Cys—f5O2 






Fig 4.1 Synthesis of IL-8: chemical ligation via Cys side-chain 
Chemical ligation of peptide fragments would therefore seem an attractive approach 
to the synthesis of proteins. However, the methods have certain limitations. The 
thioester surrogate amide bond is unstable at elevated pH and while the thioether is an 
attractive alternative both result in the introduction of an altered backbone structure 
into the protein. Whilst these factors were unimportant in the case of HIV-1 
protease, the general application of these methods remains to be demotistrated in 
other systems. 
Union of fragments via the formation of the native amide bond still remains the most 
obvious choice and, although this has been achieved using chemical ligation, as in the 
case of IL-8, the method is restricted to union at cysteine residues only. Thus, a more 
general approach to fragment coupling would be favourable. 
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4.2.2 Enzyme catalysed amide bond formation 
Normally, enzymes catalyse the degradation of proteins and peptides by hydrolytic 
cleavage of the peptide bond. However, developments in peptide synthesis have 
shown that proteolytic enzymes can be used to catalyse the formation of amide bonds 
by reversing the hydrolysis reaction.'' 8 
One of the major enzymatically catalysed systems involves displacement of the 
equilibrium in favour of amide bond formation. To achieve this the product peptide 
from the bond forming reaction must be removed from the system either by 
precipitation 19 or by use of a compound that forms a specific complex with the 
product removing it from the equilibriuni, 20 e.g. monoclonal antibody. Biphasic 
systems are also successful in removing the target peptide from solution. In this case 
the peptide passes out of the aqueous phase into an organic solvent as it is formed 
which, once again, perturbs the system, shifting the balance of the equilibrium in a 
favourable direction .21 
The advantages of enzyme catalysed coupling are that it is fast and racemisation free 
and requires only minimally protected fragments. 
4.2.3 Amide bond formation utilising the azide method 
The azide method for the formation of the peptide bond was introduced by Curtius 
over seventy years ag0 22 and, to date, is one of the most successifil amide bond 
segment condensation methods. 
Azide couplings are advantageous in that the starting materials are easily prepared, it 
leads to the least raceujisation during coupling and once the azide has been selectively 
introduced at the C-terminus, it is only necessary to protect the side-chain amino 
function of lysine (63) and the suiphydryl function of cysteine (64)23 
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(63) 	 (64) 
The azide method has been applied with success in the synthesis of ribonuclease A, 24 
secretin 111 25 and derivatives of ribonuclease T 26 to name but a few. 
Generally azides can be generated in two ways, either directly using 
thphenylphosphorazidate 27 (65) and a carboxylic acid or via the hydrazide (66). 
Formation via the hydrazide is the preferred route as the former method requires that 




N3 	 0 
(65) (66) 
Hydrazides can be incorporated into the C-terminus of peptides by treating a C-
terminal alkyl ester with hydrazine. This lends itself well to SPPS since the peptide is 
held to the resin through an alkyl ester bond (67). Hydrazinolysis of the peptide from 
the resin followed by acidolysis to remove the side-chain protection yields the peptide 







PEPTIDE!—C — NFTh;F12 
(68) 
4.2 Formation of a 	 via 	 an ester 
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Although some hydrazinolysis can occur at the t-butyl protected Asp and G1u 28 ' 29 
residues this can be minimised by using only rapid contact with dilute hydrazine 
(typically 2% aqueous hydrazine for 2-3 minutes). 30 However, there are some 
significant disadvantages with the method as hydrazine can deprotect Fmoc froth the 
N-terminus3 ' and there is also evidence that side reactions with the guanidine flinction 
of Arg can occur to give omithine or aminoguanidine. 32 
The development of hydrazine resin linkers such as (18) (Section 1.4.2) has eliminated 










Fig 4.3 Formation ofapeptide Isydrazide via a linker 
This technique selectively incorporates the hydrazide to the C-terminal carboxyl of the 
protected peptide on the solid support (69) and acidolysis on completion of the 
synthesis then yields the peptide hydrazide (70). 
The subsequent conversion of the hydrazide to the azide has been traditionally carried 
out using the Curtius procedure 33  which utilises aqueous acid and sodium nitrite. 
However, the Honzl-Rudinger method 34  (Fig 4.4) is far superior. 
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PEPTIDEI—C--NHNH2 HCI - PEPTIDEf—C---NHNH--N0 8
t) 	ONOf 
(70) (71) 
______ 	_____ __ H 
PEVFIDEf—C—N 3 - 	PEPTIDEf—C—t1—N=N-0H 
(72) 
Fig 4.4 Azideformation via the Hon ri-Rudinger method 
Reacting the peptide hydrazide (70) with an alkyl nitrite such as t-butyl nitrite 
generates an N-nitroso intermediate (71) which, on loss of water, forms the 
corresponding peptide azide (72). However, the azide (72) itself is prone to Curtius 
rearrangement to give the isocyanate (731' 
), 
which can react with the amine component 
to form a urea derivative (74) (Fig 4.5). This can be suppressed by maintaining the 
temperature at -10 °C and by immediate addition of the amine component once azide 










Fig 4.5 Urea formation via Curtius rearrangement of the azide 
Another notable side-reaction is amide formation, occurring when the N-nitroso 
intermediate (71) loses N20 to form the unreactive amide (75) (Fig 4.6). 
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Fig 4.6 Decomposition of the N.-nitroso intermediate to an amide 
Despite these side reactions, the azide procedure is a very powerful method for 
fragment coupling using minimally protected fragments. One major problem exists, 
however, namely combining Fmoc SPPS with azide condensation. The combination 
requires protection for the strongly nucleophilic N flinction of lysine and the 
sulphydryl fUnction of cysteine, both throughout the synthesis of the fragment itself 
and during the condensation of the fragments to form the desired product. This is a 
difficult problem as the protecting groups must not only be orthogonal to the 
deprotection conditions for Fmoc but must also be stable to acid. In addition to these 
stringent requirements the group should preferrably be of a nature that would aid 
solubility of the fragment and be cleavable under mild conditions. 
63 
Chapter four: Convergent Synthesis 
4.3 References 
B. Gutte and it B. Merrifield, .1. Rio!. Chem., 1971, 246, 1922-1941. 
I. Clark-Lewis, it Abersold, H. Ziltener, J. W. Schrader, L. E. Hood and S. B. 
H. Kent, Science, 1986, 231, 134-139. 
C. H. Li, D. Yamashiro, D. Gospodarowicz, S. L. Kaplan and G. van flet, 
Proc. NaIL Acad. Sci. USA, 1983, 80,2216-2220. 
W. F. Heath and It B. Merrifield, Proc. NaIL Acad. Sci. USA, 1986, 83, 6367-
6371. 
I. Clark-Lewis, B. Moser, A. Walz, M. Baggiolini, G. J. Scott and it Abersold, 
Biochemistry, 1991, 30, 3128-3184. 
J. Schneider and S. B. H. Kent, Cell, 1988, 54, 363-368. 
it F. Nutt, S. F. Brady, P. L. Darke, T. M. Ciccarone, D. Colton, E. M. Nun, J. 
A. Itodkey, C. D. Bennett, L. H. Waxman, I. S. Sigal, P. S. Anderson and A. F. 
Veber, Proc. Natl. Acad. Sci. USA, 1988, 85, 7129-7133. 
It Ramage, J. Green and 0. M. Ojunjobi, Tet. Lett., 1987, 30, 2149-2153. 
M. Kohmura, N. Nio and Y. Ariyoshi, J. Biol. Chem., 1991, 55, 539-545. 
G. H. Morton, Personal Communication, Edinburgh University. 
L. Jiang, Personal Communication, Edinburgh University. 
T. W. Muir and S. B. H. Kent, Biotechnology, 1993, 4, 420-427. 
M. Scholzner and S. B. H. Kent, Science, 1992, 256, 221-225. 
P. E. Dawson, T. W. Muir, I. Clark-Lewis and S. B. H. Kent, Science, 1994, 
266, 776-779. 
D. R. Englebretsen, B. G. Gamham, D. A. Bergman and P. F. Alewood, TeL 
Lett., 1995, 36, 8871-8874. 
G. A. Homandberg and M. Laskowski Jr., Biochemistry, 1979, 18, 586-592. 
L. Graf and C. H. Li, Biochemistry, 1981, 78, 6135-6138. 
P. Clapes, J-L. Tones and P. Adlercreutz, Bioorg. and Med Chem., 3,245- 
255. 
Chapter four: Convergent Synthesis 
H. D. Jakubke, P. Kuhl and A. Konnecke, Angew. Chem. mt. Ed Engl., 1985, 
24,85-93. 
G. A. Homandberg, A. Komiriya and I. M. Chaiken, Biochemistry, 1982, 21, 
3385-3389.9 
G. A. Homandberg, J. A. Maths and M. Jaskowski Jr., Biochemistry., 1978, 17, 
5220-5227. 
Y. S. Klausner and M. Bodanzky, Synthesis, 1974, 8, 549-559. 
It Hirschmann et a!, J. Am. Chem. Soc., 1966, 91, 502-507. 
N. Fujii and H. Yajima, I C. S. Perkin I, 1981, 789-841. 
M. A. Ondetti, V. L. Narayanan, M. Saltza, J. T. Sheehan, E. F. Sabo and M. 
Bodanzky, I. Am. Chem. Soc., 1968, 90, 4711-4715. 
J. Beacham, G. Dupuis, F. M. Finn, H. T. Storey, C. Yanaihara, N. Yanaihara 
and K Hofmann, I. Am. Chem. Soc., 1971, 93, 5526-5539. 
T. Shioiri, K Ninoxniya and S. Yamada, I Am. Chem. Soc., 1972, 94, 6203-
6205. 
E. Scoffiw, F. Marchiori, A. M. Tamburro and R. Rocchi, Gazz. Chim. ItaL, 
1964, 94, 695-709. 
B. Weinstein, R. M. Cook and J. T. Hefferman, hit. I. Pept. Prot Res., 1976, 8, 
21-25. 
J. Meienhofer, E. Schnabel and D. Gillessen, Liebigs Ann. Chem., 1963, 667, 
164. 
L. A. Carpino and G. Y. Han, J. Org. Chem., 1972, 37, 3404-3409. 
W. Danho and C. H. Li, mt. I. Pept Prot Res., 1971, 3, 81-92. 
K. A. Boissonas, S. Guttmann, P. A. Jaquenord and J. P. Wailer, 1955, Helv. 
Chirn. Acta., 38, 1491-1501. 
P. Seiber eta!, Helv. C/urn. Acta., 1970, 53, 2135 
65 
Chapter five: NLysine Protection for use in Fragment Coupling 
5. N'-Lysine Protection for use in Fragment Coupling 
5.1 Introduction 
As mentioned in Chapter 4 when azide fragment coupling (FC) is carried out on 
components containing lysine and cysteine residues, it is necessary to temporarily 
mask the chemical reactivity of theft side-chains to prevent chemical coupling 
reactions at these sites. In addition to this it is also necessary to protect the N"-
terminal amino group of the azide component preventing it from reacting with itself. 
The Fmoc N" protecting group used in SPPS is stable to the acidic conditions 
required for resin peptide cleavage, therefore if it is retained on the N-terminus of the 
hydrazide component after synthesis it can be used as an effective blocking group for 
the N" function during FC. 
The sulphhydryl function of cysteine can be protected using the acetamidomethyl 
(Acm) group as it is stable to the acidic and basic conditions required for Fmoc 
methodology and is also retained during azide FC. 
Lysine must be protected either throughout synthesis with a group stable to both acid 
and base, or be reprotected following cleavage from the resin. The latter is achieved 
by treatment with a capping agent which temporarily blocks all exposed amino 
functions during FC. Lysine, usually protected with the acid labile Boc group, can be 
reprotected with Boc after cleavage via its azide' or symmetrical anhydride 
,2 
however, Boc has been found to cleave under the acidic conditions of the Honzl 
Rudinger procedure (Chapter 4). 
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Other groups, which are introduced onto the lysine side-chain post cleavage, have 
been investigated 1 ' 38 but all have major drawbacks in that incomplete capping of the 
N8 fUnction takes place or capping of fUnctionalities other than amines occurs. In 
addition, removal of these protecting groups can be incomplete or damaging to the 
final peptide product. 
Thus, it would be highly desirable to develop an Nt protecting group which could be 
introduced, with lysine, as the peptide chain is being assembled. This group would 
have to be stable to all the conditions mentioned above and easily removed so as not 
to cause damage to the final product. Several such groups have been proposed using 
a variety of orthogonal deprotection strategies 916 but, despite this, no ideal derivative 
has been discovered. 
5.2 Penicillin Acylase Cleaved NC  Protecting Groups 
Penicillin acylase (E.C. 3.5. 1. 11) which normally catalyses the hydrolysis of penicillin 
G (76) into 6-amino penicilhinic acid (77) and phenyl acetic acid (7g)17  (Fig 5.1) has 
also been shown to cleave phenylacetyl (Phenac) derivatives. 
7O2H 
0 
H2N 	 + 	OH 
CO2H C (77) 	 (78) 
Fig 5.1 The hydrolysis of penicillin G with penicillin acylase 
Its role as a selective hydrolysis reagent for N-Phenac lysine was first demonstrated 
by Brtnik ci al in the solution synthesis of vasopressin.' 8 On completion of the 
synthesis, the Phenac lysyl peptide (79) was simply deprotected by incubating with the 
enzyme in solution to give the lysyl derivative (80) (Fig 5.2). 
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NH 	 NI; 
PeuicllUn  
---- HN 	co---- 	AcytasC 	----us 	co---- 
(79) 	 (80) 
Fig 5.2 Hydrolysis of a phenylacetyl lysine residue with penicillin acylase 
The potential advantages of such a protecting group are obvious. The amide bond 
formed should be as stable as the rest of the peptide bonds in the molecule and its 
resistance to acid and base is almost guaranteed. 
5.2.1 Nt-Phenylacetyl-lysine and other derivatives 
The Phenac protecting group has been found successful in FC reactions performed in 
this laboratory. 2° However, it was found that a typical deprotection required several 
days utilising conditions (40-50°C, pH 7.1-8.5) that are not ideal for many peptides, 
especially those which are readily hydrolised or oxidised. 
One of the major problems associated with NC  lysyl capping is the loss of protonation 
sites on the peptide and hence decreased solubility. A more hydrophilic protecting 
group would therefore be highly desirable, as would a group whose electronic 
properties made it more susceptable to cleavage. 
Several workers have carried out research attempting to discover different substrates 
for penicillin acylase 2 ' and although this work was mainly directed towards penicillin 
chemistry, an improved substrate could be a potential protecting group. It was 
discovered that 4-hydroxybenzylpenicil]in (81) was the only substrate of those tried 
which cleaved faster than penicillin G. The corresponding N protecting group would 
be the 4-hydroxyphenylacetyl (Hopa) group (82). 
M.-  




This increased rate of hydrolysis can be rationally explained by modelling substrates 
within the active site of penicillin acylase, the crystal structure of which has recently 
been reported. 12 
The benzyl moiety is held in the active site by a hydrophobic cleft formed by three 
phenylalaime residues. At the front of this cleft is a 131 serine residue which is 
responsible for the hydrolysis of the amide bond. However at the back of this cleft is 
a second serine which could hydrogen bond to a ftinction at the 4 position, drawing it 
quickly into the active site. Tne subsirai.e is then held there until hydrolysis is 
complete. Fig 5.3 shows a molecular model of the phenylacetyl derivative in the 
active site. As can be seen, modifications other than those at the 4 position would 
interfere with the hydrophobic phenylalanine residues causing a worse fit into the cleft 







Fig 5.3 Molecular model of the active site of penicillin acylase hydrolysing the 
ph enylacetyl substrate 
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5.2.1.1 Synthesis of N"-Fmoc-4-t-butoxyphenylacetyl-lysine: initial observations 
In order to incorporate the Hopa lysine residue into a peptide the hydroxy fimction of 
the protecting group must itself be protected during synthesis. Normally such 
fhnctions are protected as the acid labile t-butyl ether therefore Hopa was protected in 
this way. The amino acid derivative introduced onto the synthesiser would then be 
NaFmoc.4tbutoxyphenylacetyl1ysine  (Fmoc-Lys-Bupa) (91), cleavage of the 
peptide from the resin would regenerate the Hopa derivative which could then be 
cleaved after FC using the enzyme acylase. 
Palm 20 attempted to synthesise (91) (Scheme 5.1) using the same route as that 
devised for the Phenac derivative but the synthesis proved to be very difficult and 
problems arose on removal of copper from the copper-Lys(Bupa) complex (89) with 
EDTA. However, it was found that the complex could be broken up using sulphur 
containing compounds and that, of the reagents tried, ammonium sulphate was the 
most successful. Fmoc was attached without any problems but the product could not 
be crystallised or obtained in purity. Despite this a small pentapeptide, H-Phe-Gly-
Lys-Ala-Gly-OH, with lysine Hopa protected was prepared and tested against the 
same sequence with lysine Phenac protected. Two exciting results were found: not 
only did the Hopa group give increased solubility over Phenac, but it cleaved almost 
four times as fast as the Phenac group. As this appeared to be such a promising 
protecting group for FC it was desirable to optimise the synthesis to improve on yield 
and purity. 
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(90) 	) -ç 	O IIW 'CO2H (91) 
Scheme 5.1 Synthesis of Fmoc-Lys-Bupa 
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5.2.1.2 Investigation into the synthesis of Na_Fmoc4_t_butoxyphenyIacetyI_ 
lysine 
Palm's synthesis was repeated first of all, but, it was found after a number of attempts 
that removal of copper from (89) using ammonium sulphide was very difficult and the 
synthesis was not reproducible by this route. Therefore a different approach was 
tried. Attempts were made to couple Bupa directly to the N amino function of N"-
Fmoc-lysine using either the acid chloride or various activated esters, but all proved to 
be impossible. Attempts to couple to the Z-lysine derivative were also fruitless (Table 
8). 
Table 8 Attempted syntheses of Fmoc-Lys-Bupa 
Y= Fmoc or Z 
Bupa Activation Y-Lys Y-Lys-Tos Y-Lys-TMS 
Acid chloride x x x 
HOCt ester x x x 
HOEt ester x x x 
Succinamide ester x x x 
At this point the copper route was attempted again. The acid chloride (88) was used 
as the active species and used immediately, adding it dropwise to a solution of the 
lysine copper complex (84) in water while maintaining the pH of the reaction at 10. A 
blue precipitate formed which corresponded to the copper-lysine(Bupa) complex (89). 
As sulphur compounds had proven to be unproductive at copper removal in previous 
experiments the disodium salt of EDTA was tried instead. It was found that using 
high dilution and stoichiometric amounts of EDTA the desired product (90) could be 
obtained in 48% yield. The N" protecting group (Fmoc) was then attached to the N-
terminus using Fmoc-ONSu (92) to give the pure amino acid derivative (91), but only 
a very poor yield (2%) was obtained. 
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(92) 
Several attempts were made to improve on this but each filled and problems started 
to arise during incorporation of Bupa into the copper-lysine complex (89). Due to the 
random variation in results found in this research, in Palm's work and the 
irreproducibility of the syntheses, it is thought that Bupa becomes unstable when 
activated due to a combination of the inductive effect and the mesomeric effect 
inherent in the compound. 
When Bupa is activated as the acid chloride there is a strong pull of electrons away 
from the t-butyl group which can leave forming an extremely stable carbocation. The 
remainder of the molecule is then stabilised due to the mesomeric effect and as a 
result of this resonance stabilisation can survive. 
5.2.1.3 Synthesis and studies on N"-Fmoc-4-methoxyphenylacetyl-lysine 
It was evident from the number of problems encountered with Bupa that a different 
protecting group was required. The p-methoxyphenylacetyl (Mepa) derivative (93) 
was chosen as it is stable when activated and molecular modelling studies have shown 
that it is structurally compatible with the active site. Thus Mepa should hydrolyse as 
fast as Hopa since the oxygen at the para position should still be available for 
hydrogen bonding with the serine residue in the active site. 
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Fmoc-Lys(Mepa) (93) was synthesised using the procedure developed for Fmoc-
Lys(Bupa) (Scheme 5.1). The synthesis proceeded without any difficulty and the final 
product was obtained in approximately 60% yield. The group's solubility when 
incorporated into a peptide and its relative rate of hydrolysis were investigated and 
compared with results obtained by Pallin for the Phenac and Hopa derivatives. The 
same model peptide (H-Phe-Gly-Lys-Ala-Gly-OH) as used by Pallin was synthesised 
with lysine Mepa protected. Unfortunately the results were very disappointing. Not 
only did the Mepa protecting group render the peptide even more hydrophobic than 
the Phenac derivative (Fig 5.3) but it had a slower rate of hydrolysis (191h as opposed 
to 5 lh). This would suggest that the largest group tolerated at the para position of 
phenylacetyl in the active site is the hydroxyl as even the methyl group seems to 
hinder access of the the serine residue to hydrogen bond to the oxygen. 
Mepa, R = 13,43%B 	
Phenac, R = 11, 37%B, 
20 	 Rt (minutes) 	 0 
Fig 5.3 HPLC trace illustrating djffernce in it between Mepa and Phenac 
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Following these disappointing results a method was found in the literature which 
reported cleavage of the methyl ether of tyrosine to the hydroxy function using a 
thioanisole-TFMSA acid system. 23 It was thought this method could be applied to the 
Mepa protected pentapeptide in order to generate the Hopa derivative which as 
explained above is more desirable. The peptide was stirred in the same cocktail but 
only partial cleavage was observed even after 2.5h. The Mepa protecting group was 
abandoned at this point due to the long time required to cleave the methyl ether as this 
could be destructive to large polypeptide chains. 










Fig 5.4 TFA cleavage of the benzyl ether to generate Hopa 
Further investigation into this area by Draffan 24 has led to the development of a 
suitable protecting group for lysine. It was found that the Hopa derivative could be 
incorporated successfully onto the side-chain of lysine, using Scheme 5.1, if the 
hydroxy function was protected via a benzyl ether (94), (Fig 5.4). Cleavage of the 
ben.zyl ether to regenerate Hopa is compatible to the conditions used in cleaving the 
peptide from the resin (TFA). Chapter 7 discusses the utility of the group in azide 
FC. 
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6. Investigations into Fragment Coupling Utilising Novel 
Lysine Protection 
6.1 Introduction 
With the new 4-benzyloxyphenacetyl (Bepa) (94) protecting group in hand, (Chapter 
5) it was desirable to test its ability to withstand the conditions necessary for azide 
fragment coupling (FC). Draffan' had already tested its durability during SPPS by 
incorporating it into the model pentapeptide system (Phe-Gly-Lys-Ala-Gly) and had 
shown that cleavage of the peptide from the resin with TFA also cleaved the benzyl 
ether to give the Hopa derivative (82) as expected. Deprotection of this single Hopa 
protected lysine residue with penicillin acylase was fast (-24h) and the results were 
comparible to those obtained by Palm 2 for this system. 
Salmon Calcitonin I (SCT) was chosen as a model system as this had already been 
synthesised by Pallin using the azide FC technique when testing Phenac as a suitable 
protecting group for lysine. 
SCT3 is a 32 residue peptide hormone with an amino terminal 1-7 clisuphide bridge 
and a prolinamide at the carboxyl terminus 45 (95) (Fig 6.1). A calcitonin is a peptide 
hormone produced in the thyroid gland of mammals or the ultimobranchial gland of 
birds and fish. It is secreted in response to high calcium levels in the blood and has a 
regulatory function in the calcium phosphorous metabolism. 6 The calcitonins are 
widely used as drugs combating various bone metabolism disorders such as Pagets 
disease,' hypercalcemia 8 and osteoporosis. 9 Fish calcitonins are generally more potent 
than mammalian calcitonins, possibly due to reduced degradation,' ° and are currently 
used therapeutically. 
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32 
(95) 
Fig 6.1 Amino acid sequence of SCT 
There have been several syntheses of the calcitonins, some utilising the filly protected 
fragment approach" and others utilising the enzymatic coupling approach; 12  thus no 
problems were envisaged for this synthesis 
Pallin chose to couple fragments 1-10 and 11-32 of the calcitonin (Fig 6.1) using the 
azide FC technique. This meant the amide bond to be formed lay between ' °Gly and 
"Lys. Conversion of glycine to the azide avoids both racemisation of the azide and 
minimises steric interaction during coupling, though conveniently, the cut happens to 
he between the "head" and the "tail" of the peptide. Thus the same fragments were 
chosen again for the synthesis with lysine Bepa protected. 
Both components to be coupled required derivatisation of their C-terminal residues 
and this could be achieved simply by utilising the versatile dibenzosuberone derived 
linker (17) for the C-terminal hydrazide (fragment 1-10) and (18) for the C-terminal 
amide (fragment 11-32). Thus, before embarking on a synthesis of the fragments to 
be coupled, the linker had to be synthesised. 
6.2 Synthesis of the Dibenzosuberone Linker 
The linker (102) was synthesised with no major difficulties using the synthetic route 
(Scheme 6.1) devised by MInnes 13 and Irving. 14 
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Scheme 6.1 Synthesis of dibenzosuberone linker 
Once the linker is synthesised the next step is attachment to a solid support and 
subsequent reactions are then carried out while the linker is immobilised. 
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The first step is reduction of the ketone function, which is then reacted with the 
appropriate reagent in order to derivatise the linker to suit the functionality required at 
the C-terminus, be it the hydrazide or the amide. 
Irving utilised aminomethylated polystyrene resin (103) as a support for the linker 
(102). This allowed the resin fimctionality to be controlled by monitoring the amount 
of remaining free amine (Kaiser test) which could then be capped to prevent further 
reaction during synthesis of a peptide e.g. low resin loadings are required for large 
polypeptides. This support also provided a strong amide bond between the linker and 
the resin. 
(103) 
Problems were encountered, however, while reproducing Irving's work. It was found 
that the support contained fines which prevented the resin from swelling sufficiently. 
This prohibited access of reagents to the linker, as well as blocking the filters on the 
peptide synthsiser. New batches of resin were purchased but these were equally 
unsuitable. Therefore a different support had to be used. The p-aminomethylated 
(PAM) resin (104), which is functionalised by an amino acid, still has all the 
advantages of the aminomethylated resin and was shown to be free of fines. 
H2NCH(R)C0CH2_rj)__CH2CNHCH2_t}_ ['E) 
(104) 
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Unfortunately difficulties still ocurred after reduction of the ketone as the resulting 
system, unless used immediately, appeared to be unstable. Despite this, material was 
obtained that was suitable for use on the synthesiser but a more stable system would 
obviously be preferrable. 
The chioromethylated polystyrene (Merrifield) resin (105) had previously been used 
by M"Innes. This involves attachment of the linker (100) to the support via its 
caesium salt (106) forming a strong and stable ether linkage (107). The only 
disadvantage in this system is controlling the resin ftmctionality and it was for this 
reason that the aminomethylated resin (105) was investigated by Irving. M'lnnes's 
synthesis was repeated (Scheme 6.2) and when the ketone was reduced the resulting 
system was found to be extremely stable. 
ct-c 
(105) 
The linker was then flinctionalised forming either the C-terminal hydrazide (18) or 
amide (17) by reaction with the Boc hydrazine or Fmoc carbamate respectively 
(Scheme 6.2). 
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Scheme 6.2 Synthesis of hydrazide and amide linker via attachment to 
cli loromethylated polystyrene resin. 
6.3 Synthesis of Protected Fragments of SCT for Azide Fragment 
Coupling 
The first amino acid, in the hydrazide fragment (109), Fmoc-Gly-OH, was coupled 
manually to linker (18) via its acid chloride. The rest of the chain was then assembled 
on the synthesiser employing standard HOBt coupling conditions. Several syntheses 
of this fragment were attempted before a suitable combination of protecting groups 
for the N-terminus and the side-chain of cysteine were found. 
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Palm, in his synthesis, protected cysteine with the Acm sulphydiyl protecting group 
and used Fmoc for protection at the N" position. However, the combination of the 
Acm groups with Fmoc formed an extremely hydrophobic peptide which was very 
difficult to purify. Thus, for this investigation it was desirable to produce the peptide 
in a more soluble form to avoid difficulties in purification. 
It was proposed that the hydrazide fragment could be coupled without cysteine 
protection to improve the solubility of the peptide if the cysteines were oxidised 
beforehand, forming the disulphide bridge and thus preventing them from taking part 
during azide FC. The cysteine residues were therefore protected during synthesis 
with the trityl group which is acid labile and is cleaved when the peptide is released 
from the resin with TFA. Whilst in theory this should have been possible, attempts to 
synthesise the trityl protected peptide failed. The coupling efficiency dropped 
dramatically (-30%) after coupling the last residue in the fragment which is 'Cys(Trt). 
Attempts to improve this employing extended double coupling cycles and manual 
coupling in a sonic bath were equally fruitless. The dramatic drop in coupling 
efficiency is probably caused by steric hindrance from the 'Bu side-chain protecting 
group on 2 Ser to which the bulky 'Cys(Trt) residue is to be coupled. Thus, this route 
was abandoned and Acm protection had to be used. 
Further research within the group' 5 showed that Hopa could be used successfully as 
an N"-protecting group in SPPS and that it could aid solubility of peptide fragments 
not normally soluble with the Fmoc group. Thus, it was hoped that by switching to 
Hopa for N"-protection in the SCT 1-10 synthesis that this would aid solubility of the 
Acm protected fragment for purification. This worked very well and solubility of the 
fragment improved dramatically compared to Palm's synthesis. The fragment (109) 
(Fig 6.2), now mostly soluble in aqueous media, was purified by RP HPLC in a 28% 
yield. 
Chapter six: Investigations into Fragment Coupling Utilising Novel Lysine Protection 
The amine component (I 11) (Fig 6.2) is a peptide amide and was synthesised using 
the linker (17). "Lys and "Lys were coupled as their Bepa derivatives without any 
problems and the crude peptide was purified using the Thfinoc/carbon procedure 
(Chapter 3). The yield of this peptide was lower than expected (-19%) but it was 
discovered later that this was due to an inaccurate initial resin ftmctionality. The 
cleavage time, initially carried out for 5h, had to be repeated for a further 3h on the 
crude material as MS analysis showed evidence of incomplete cleavage of the benzyl 
ether on the Bepa protecting group to the Hopa derivative. 
6.4 Azide Coupling of Protected Fragments of SCT 
1 	 10 
Hopa-NH-Cys-Ser-Asn-Leu-Ser-T1irCys-VaI-LeuGly—N HNH 2 
Ann 	 Am 	(109) 
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The peptide hydrazide (109) was converted to the peptide azide (110) smoothly by 
the addition of t-butyl nitrite at low temperature. On addition of the amine 
component (I 11) the reaction was stored at 0°C for 24h. More azide was added and 
after a fhrther 24h a third aliquot of azide was added as some amine component still 
remained unreacted. The coupling was monitored by HPLC (Fig 6.3) and was 
stopped after 4 days as no thrther reaction was observed. The product (112) was 
isolated by RP FIPLC in 20% yield. 
Fig 6.3 IIPLC traces showing the progress of the azide coupling of SCT(1- 
10) (110) and SCT (11-32) (111) 
M. 
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6.4.1 Enzyme deprotection of SCT 1-32 (Acm) 2(llopa)3 
Once the protected product peptide (112) had been isolated the N-terminal Hopa 
group and the Hopa lysine protecting groups were removed using immobilised 
penicillin acylase, incubating at 37°C and pH 8.1. Deprotection took only 48h and the 
final product (113) was isolated by filtration to remove the resin bound enzyme, 
followed by purification by HPLC which resulted in a very poor yield (2%). Due to 
the low yield there was insufficient material to carry out an Acm deprotection and 
obtain analysis therefore the Acm groups were not removed from cysteine. It was 
thought that the low yield was due to the peptide chain binding to the resin on which 
penicillin acylase is immobilised. The synthesis was not optimised due to other 
developments within the research group concerning Bepa. These are mentioned 
below. 
6.5 Summary 
Studies using SCT have shown that Bepa is a suitable protecting group for use in the 
azide fragment condensation technique but a more suitable support for the enzyme is 
required. However, recent investigations' have shown that this protecting group 
strategy is only applicable to small peptide systems since no deprotection of the lysine 
residues was observed when Bepa was incorporated into a larger polypeptide system, 
namely ubiquitin (76 residues of which 7 are lysine). 
Fig 6.4 shows the 3-D crystal structure of the enzyme which might provide some 
explanation to the differences observed in the deprotection of small systems as 
opposed to larger peptide systems. The B chain N-terminal serine, responsible for 
hydrolysis, is just discernable at the apex of the 13-strand buried deep in the centre of 
the molecule. Clearly the relative inaccessability of the active site means that, whilst 
small unstructured molecules are allowed access to the binding pocket and are rapidly 
0 
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deacetylated, larger protein molecules (which can adopt some degree of structure 
under the reaction conditions) are less likely to be deprotected, if at all. 
Fig 6.4 iVJOLScR1PT represeutatic;; of the 3-0 rrctal structure of penicillin 
aclase (left) Blue = A chain, Red = B chain showing ball and stick active site 
serine side chain and (right) an orthogonal view, coloured as described 
1 14 
6.6 Recent Developments in Lysine Protection 
Base 
RE 
Fig 65 Tnm protecting group for Nfunction of lysine: cleavage conditions 
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Owing to these results, a completely new approach to lysine protection had to be 
adopted. Comer 16  recently developed a group, which has found application in lysine 
protection.' The protecting group, referred to as Turn (114), is stable to all the 
conditions required for Fmoc SPPS, but cleaves at the acetal during acid cleavage of 
the peptide from the resin to yield a protecting group (115) which is more solubilising 
and which now may be cleaved under mildly basic conditions (Fig 6.5). The group 
has been incorporated into ubiquitin' and has been shown to deprotect easily from the 
lysine residues. 
6.7 Preliminary Investigations into the Stability of the Trim Group 
for Fragment Coupling 
6.7.1 Azide fragment coupling 
It was mentioned in Chapter 3 that a convergent synthesis of dhEPO may be better 
yielding than the stepwise synthesis of the protein. Thus, in order to test the stability 
of the Turn group to FC, two small fragments of hEPO (Fig 6.6) were chosen as a 
model for an azide FC. 
103 	 112 
Fmc-NH-Azg-Ser-Leu-Thr-Thr-LeuAi-Ma-1sii-Gly-NllNft2 
(116) 
113 	 125 
ft2N-AinLys-Gbi-Ala-HeSerPiu-Pm-As p-Ala-Ala-Oft 
Tnm 	(117) 
Fig 6.6 Proposed protectedfragments of hEPO for azide fragment coupling 
Coupling between 112Gly and "'Ala seemed to be the most appropriate site in the 
protein sequence (Fig 3.1 Chapter 3) since glycine cannot racemise and coupling to 
Ala should minimise steric interactions. Ain attempt was made to synthesise the 
hydrazide fragment (116) but problems arose after 107Thr was coupled. The next 
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amino acid in the sequence was 106TLM  but coupling this residue proved to be virtually 
impossible, even after extended double coupling cycles were employed followed by 
additional coupling in a sonic bath. Obviously this difficulty was not envisaged when 
choosing appropriate fragments since the chain assembly for the entire protein had 
proceeded smoothly. One possible explanation for this is that the isolated fragment is 
too hydrophobic in the absence of the rest of the protein chain. This means that the 
growing chain of the small peptide can interact with the resin causing the chain to 
wrap itself tightly around its surface. This would render the N-terminus inaccessable 
to the next activated amino acid which would explain why Tlir  would not couple to 
' °7Thr. Despite this, more suitable fragments were not chosen as it was more 
important to demonstrate the utility of the Trutt protecting group in FC. Thus the 
hydrazide fragment was synthesised once more but only as far as 107Thr (118) and the 
amino component (117) was assembled with no apparent difficulties (Fig 6.7). 
107 	 112 
flmc -t4ThTIr-LewArg-AIa-Leu-GIy-NHNH2 
 
t-butyl nitrite, 4M HG 
4, DMF 	
113 	 125 






107 	 125 
NBhr.LeuArg-Ma-LeuCly-Ma-G1n-Lys -Clu-Ma-IIe -Ser-Pro-Pro-Asp-Ala-AIa-OH 
 
Fig 67 Azide fragment coupling of two fragments of JIEPO utilising the Thin 
The hydrazide (I 18) was converted to the azide (119) and the segments were coupled 
in exactly the same way as described for SCT (Fig 6.7). Coupling was monitored by 
HPLC (Fig 6.8) and proceeded smoothly. MS analysis of the final product showed 
~WOH 
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that the Tnm group had not cleaved in the azide coupling mixture and thus is suitable 
for azide FC. The protected product peptide (120) was isolated by HIPLC and lysine 
protection along with Fmoc N" protection were removed simultaneously with a 10% 
piperidine solution to give the filly deprotected product peptide (121). 
unreacted hydrazide 11 IT Omins 
protected product peptide 
IT3h I 
unreacted hydrazide 
protected product peptide amine component has 
almost disappeared 





Fig 6.8 IIPLC traces showing azide fragment coupling of two small fragm ents of 
hEPO with lysine protected with Tnm  
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6.7.2 Ester fragment coupling: preliminary investigation 
Coupling peptide fragments via the active ester has been carried out successfully by 
some groups. 17  However, this technique has not gained as much interest as the azide 
method due to the requirement for protection of all hydroxyl and carboxylic acid side-
chains in addition to those mentioned for the azide. Despite this it has certain 
advantages over the azide route. Coupling fragments via the active ester requires less 
sensitive conditions than the azide procedure (higher temperatures can be employed) 
and an excess of the activated species is not required for coupling to proceed 
effectively (this is an important consideration for large, expensive polypeptides). It 
would, therefore, be desirable to develop a route whereby the activated ester of 
minimally protected fragments could be formed i.e only lysine and cysteine need be 
protected as in the azide method. It has been proposed that this could be achieved if 
the minimally protected peptide azide was formed but instead of coupling the amino 
component the azide is first converted to the active ester by reacting it with HOCt 
(Fig 6.9). Forming the active ester in this way would not require DIC thus hydroxyl 
and carboxylic side-chains need not be protected. 
EIO2C 	N 	 0 	 CO2Et 




Fig 6.9 Formation of the active HOCt ester via the azide for use in ester fragment 
coupling 
The method was applied to the two small fragments of hEPO used in the azide 
coupling described above (Fig 6.7). Three equivalents of HOCt were used for 
conversion of the azide to the active ester and additional base was added (molar 
equivalent to HOCt) to compensate for the acidity of HOCt. The coupling was 
monitored by HPLC, as before, and gave an identical profile to that obtained for the 
azide coupling (Fig 6.7). The results however, remain inconclusive at this time, as no 
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MS data could be obtained to confirm formation of the active ester. Thus, there is no 
evidence to confirm coupling actually proceeded via this active species. 
Obviously fiuther investigation is required into this area as this could provide a very 
promising method for producing minimally protected fragments for active ester 
fragment coupling. Unfortunately due to limited time this could not be taken thither. 
93 
Chapter six: Investigations into Fragment Coupling Utilising Novel Lysine Protection 
6.8 References 
L. C. Draffan, Personal Comunication, Edinburgh University. 
T. D. Palm, PhD Thesis, Edinburgh University. 
J. T. Potts, Bone and Mineral, 1992, 16, 169-173. 
I. Macintyre, in 'Endocrinology' (L. J.Degroot, Ed.), 1989, 2, 892-901. 
M. Azira, in 'The Calcitonins: Physiology and Pharmacology', pp 4-10, A. G. 
Karger, Basel, Switzerland. 
L. A. Austin and H. Heath, N. Engl. J. Med., 1981, 304, 296-297. 
A. Aurimedes, It K Baker and S. Wallach, Metabolism, 1974, 23, 1037-1046. 
D. J. Hosking and S. it Heller, Eur. J. Clin. PharmacoL, 1986, 31, 27-3 1. 
S. Wallach et al., Curr. Ther. Res., 1977, 22, 556-572. 
D. M. Findley etat,Endocrinology, 1983, 112, 1288-1291. 
P. Seiber, B. Riniker, M. Brugger, B. Kamber and W. Rittel, Helv. Chim. Acta., 
1970, 53, 2135-2150. 
M. Gondo, H. Yamashita, K. Sakakibara and Y. Isowa, Peptide Chemistry (T. 
Shiori Ed.), 1981, Protein Research Foundation, Osaka, Japan. 
C. M'lnnes, PhD Thesis, Edinburgh University. 
S. L. Irving, PhD Thesis, Edinburgh University. 
A. Kelly, Personal Comunication, Edinburgh University. 
A. J. R Corner, Personal Comunication, Edinburgh University. 
H. Benz, Synthesis, 1994, 4, 337-358. 
Chapter seven: Outlook and Conclusions 
7. Outlook and Conclusions 
The preceeding chapters have described the methodology required for both stepwise 
and convergent syntheses of proteins. The pioneering stepwise syntheses of dhEPO 
and other large proteins within the group (stromelysin', obese gene 2,3  and interferon-
y4)  have demonstrated that larger polypeptide systems previously unattainable by 
other methods are now possible to synthesise linearly, purify and characterise using 
our methodology. It would therefore be reasonable to assume that a convergent 
synthesis via the union of two large units of a polypeptide is within our reach as a 
suitable protecting group strategy now exists. Utilising convergent synthesis for the 
production of proteins should ease purification and give improved yields compared to 
those obtained from a linear synthesis. 
However, it is evident from the experimental results that the combination of the two 
techniques has to be given careful consideration and their application could. in fact be 
dictated according to protein sequence. This was apparent in the fragment coupling 
of SCT and also in the union of the two small segments of hEPO where choice of 
peptide fragments, though apparently straightforward, played an essential role in the 
FC technique. In fact, choice of peptide fragments could decide whether a PC 
synthesis is indeed a possibility for some protein sequences at all. 
Obviously much investigation is still required in this field as synthesis and purification 
are only the stepping stones to obtaining biologically important proteins. The most 
difficult challenge will be to produce these proteins in a biologically active form which 
usually requires that the protein be folded. Indeed, the precisely folded three-
dimensional structure of a protein is perhaps the ultimate synthetic goal. 
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8. Experimental 
8.1 Notes 
Sonication was carried out in a Decon FS300b sonic bath. Melting points were 
recorded in open capillaries using a Buchi 510 oil immersion melting point apparatus 
and are uncorrected. Nuclear magnetic resonance (NMR) spectra were recorded on 
either a Jeol FX-60 (60MHz), a Brucker WP-200 (200MHz), a Brucker AC-250 
(250MIHi) or a Brucker WH-360 (360MHz). UV spectra were recorded on either a 
Varian Carey 210 double beam spectrophotometer, a Perkin Elmer UV/vis single 
beam spectrophotometer or a Unicam UV/vis double beam spectrophotometer in the 
solvents described in the text. High and low resolution fast atom bombardment mass 
spectra (FAB MS) were measured on a Kratos MS50TC mass spectrometer, electron 
ionisation mass spectra (El MS) were measured on a Kratos 902 MS and matrix-
assisted laser desorption/ionisation (MALDI) time of flight mass spectra (TOF MS) 
were recorded on a PerSeptive Biosystems Voyager Biospectrometry TM  
Workstation from Vestec mass spectrometry products. Infrared spectra were 
recorded on a BlO-RAD SPC3200 instrument. Elemental analyses were performed 
on a Perkin Elmer 2400 CHN elemental analyser. All amino acids were purchased 
from Bachem with the exception of Fmoc-Lys(Phenac), Finoc-Lys(Mepa), Fmoc-
Lys(bepa), Fmoc-Lys(Tnm). Fmoc-Cys(Phenac) and Fmoc-Cys(Mepa) which were 
prepared in this laboratory by the methods described in this text, or in the texts of 
Alt Brown. A.J.R Comer and L.C. Draffan. All amino acids were of the L 
configuration. Gel filtrations were carried out on a Pharmacia LEE p500 FPLC 
system using Superdex 75 FIR 10/30 or 26/60. Amino acid analyses were 
performed on an LKB 4150 alpha amino acid analyser on the hydrosylate obtained 
from heating samples in 6N HCl at 110 °C (number of hours stated in text) in a sealed 
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Carius tube, followed by evaporation to dryness. Protein sequencing was performed 
on an ABI 477A protein sequencer at the Welmet sequencing facility, University of 
Edinburgh. High performance liquid chromatography (HPLC) was carried out using 
either an ABI system comprising 2 x 1406A solvent delivery systems, a 1480 
injector/mixer and a 1783A detector/controller, or a Gilson system comprising 2 x 
306 solvent delivery systems, an 81 1C dynamic mixer, an 805 manometric module, a 
119 UV/VIS detector and a Gilson software-driven gradient controller. Components 
were eluted from various columns, as described in the text, with a linear gradient of 
acetonitrile (%B), far liv grade (Rathburn Chemicals) in Milli-Q grade water (%A), 
where both solvents contained 0.1% v/v of HPLC grade TFA (Fisons). Peptide 
synthesis grade trifluoroacetic acid (TFA) was purchased from Applied Biosystems 
(ABI). Peptide synthesis grade dimethylformamide (DMF), 1,4-dioxane and 
piperidine were obtained from Rathburn Chemicals, Walkerburn, Scotland. 
Throughout the text ether refers to diethyl ether. 
8.2 Solid Phase Peptide Synthesis 
The polypeptides described were synthesised on an ABI 430A automated peptide 
synthesiser with on line UV monitoring using an ABI 758A detector. All 
polypeptides were synthesised using the 9-fluorenyhuethoxycarbonyl (Fmoc) strategy 
of Na protection. This involves the complementary use of orthogonal acid labile side 
chain protection and an acid labile peptide-resin linker. 
8.2.1 Side-chain protecting groups used in Fmoc SPPS 
The side-chain protecting groups were as follows: t-butyl (Bu) ethers for Ser, Thr 
and Tyr; 'Bu esters for Asp and Glu; 'r—triphenylmethyl (Trt) for His; 2,2,5,7,8- 
pentamethylchroman-6-sulphonyl (Pmc) for Arg. The carboxamide side chains of Asn 
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8.2.4 C-terminal hydrazides 
The first amino acid is loaded manually via its acid chloride and is always Fmoc-Gly-
Cl to avoid racemisation. The preparation of the hydrazide resin is given in the 
following text. 
8.2.5 The Fmoc loading test 
Dry Fmoc-amino acid resin (2-3mg), was placed in a lOml volumetric flask and 20% 
piperidine/DMIF was added to the volumetric level. The mixture was sonicated at 
room temperature for 15 minutes and the UV spectrum of the supernatant was 
recorded between 280 and 320nm. The resin fhnctionality (mmol/g) and percentage 
coupling were calculated using the Beer-Lambert law (s302 = 15400 for the flulvene 
piperidine adduct). 
8.2.6 Automated SPPS 
Synthetic procedures were preprogrammed into the ABI 430A synthesiser prior to the 
the synthesis. Each synthetic cycle, resulting in the coupling of a single amino acid, 
involved: Capping, to block any unreacted amino groups; Deprotection, to remove 
the Fmoc group from the Na position; Coupling of the next N"-Fmoc-amino acid. 
Each step was followed by thorough washing of the resin and each cycle was repeated 
with the chosen amino acid in order to build the desired polypeptide. The 
preprogrammed synthetic cycles are summarised below. 
8.2.6.1 Capping 
The resin was vortexed with a solution of acetic anhydride (0.5M), DIEA (0. 125M) 
and HOBt (0.2% w/v) in DMF:1,4-dioxane (1:1, lOml) for 10 minutes, before the 
capping solution was drained from the reaction vessel and the resin washed with 6 
portions of DMF:l,4-dioxane(l:1). 
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8.2.6.2 Deprotection 
The resin was vortexed with a solution of 20% piperidine in DMF: 1,4-dioxane (1:1, 
lOml) for 6 minutes before being drained and washed 4 times with DMF. The 
deprotection cycle was repeated twice but vortexing was only for 1.5 minutes. Finally 
the resin was washed with 6 portions of DMIF: 1,4-dioxane (1:1). 
The percentage of amino acid successfully coupled in the previous cycle was 
determined by the absorbance of the flulvene-piperidine adduct at 302nm from the first 
deprotection. An aliquot of the deprotection filtrate was passed through an UV 
detector, with on-line integration. Comparison of the area of each succesive 
deprotection peak with that of the first amino acid allowed an estimate of the 
percentage coupling of each residue. 
8.2.6.3 Coupling 
Residues were incorporated in one of two ways; either using the HOBt method, or the 
HOCt method described below. 
The HOBt method: uses double couple cycles in which the first coupling cycle 
utilises a preformed symmetrical anhydride, followed by a second coupling using a 
preformed HOBt ester. The exceptions to this were asp aragine, glutamine and 
histidine, which were coupled twice as their HOBt esters and glycine, which was 
coupled once as the symmetrical anhydride. 
Both the symmetrical anhydride and the activated ester were preformed in an 
'activation vessel' before being transferred to the reaction vessel. For symmetrical 
anhydride formation, the Fmoc-amino acid (immol) was reacted with DIC (0.5mmo1) 
in DMF: 1,4-dioxane (1:1, 8m1) for 10 minutes after which time it was transferred to 
the reaction vessel containing the resin. The mixture was vortexed for 30 minutes, the 
resin was drained and washed with 4 portions of DMF:1,4-dioxane (1:1). The resin 
was then vortexed for a second 30 minute period with the Fmoc-amino acid HOBt 
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active ester, preformed from the Fmoc-amino acid (0.5mmol), HOBt (0.5mmol) and 
DIC (0.5mmol). The resin was drained and washed with 4 portions of DMF: 1,4-
dioxane (1:1). For certain difficult couplings the coupling time was extended or, 
alternatively, a third coupling, using the HOBt ester, was included as required. 
The HOCt method: uses a single coupling cycle in which the Fmoc-amino acid HOCt 
active ester is used. The exception to this was histidine which was coupled as the 
HOBt active ester (HOBt (lmmol) was placed in the cartridge with histidine (immol) 
prior to synthesis). The HOCt active ester was preformed as for the HOBt active 
ester but a lmmol scale was used. 
8.2.7 The Kaiser test 
A sample of dried resin (between 2-3mg) was placed in a test tube and ninhydrin 
reagents according to the following ratio were added: 
Monitor 1: phenol/EtOH (75 kl) 
Monitor 2: KCN/pyridine (lOORl) 
Monitor 3: ninhydrinfEtOH (75ptl) 
The resin was incubated in a heating block at 110 °C for 7 minutes before 60% 
EtOHIH20 (4.8m]) was added. The mixture was vortexed to mix the solution 
thoroughly and the resin was allowed to settle to the bottom again. The absorbance 
(Abs) of the supernatant at 570nm was recorded using the 60% EtOIT!H20 solution 
as the standard. The percentage coupling was calculated as follows: 
mo1Jg = [Abs(saniple) x diluiion(mI)] x 10 6 
Extinction coefficient x sample weight (mg) 
Extinction coefficient = 15,000 M 1 cm 1 
Dilution = 5m1 
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% coupled = [ 
	
e(tmoVg) 	1 10 
1 03  x sub stitution(mmo]/g) j 
8.2.8 Loading Tbfmoc onto the peptide-resin 
Using the Fmoc loading test the resin functionality (mmoiig) of the peptide-resin was 
calculated. Ththioc chloroformate (3 equivalents) was sonicated in DCM until all had 
dissolved. The solution was added to the resin followed by DIEA (1 equivalent). 
Additional DCM was added if required to swell the resin fully. The mixture was 
sonicated in the dark for 3h after which time the resin was filtered, washed with 
copious DCM then ether, dried in vacuo and a Ththoc loading test was carried out. 
The resin was swollen in 1,4-dioxane and stored in the freezer until required. 
8.2.9 The Tbfmoc loading test 
Dry Thflnoc-peptide-resin (2-3mg) was placed in a lOml volumetric flask and 20% 
piperidine/1,4-dioxane was added to the volumetric level. The mixture was sonicated 
for 15 minutes. The UV spectrum of the supernatant was recorded between 340 and 
400nni. The resin functionality was calculated from the equation: 
Resin thnctionality (nimollg) = [0.613 x Abs at 364nm]/weight of resin (mg)thus, % 
loading of Thflnoc = mmoL'g (Thflnoc-peptide-resin)/mmoVg (peptide-resin) 
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8.3 Experimental Details 
Ethyl diazoacetate (41)' 
A solution of ethyl glycinate hydrochloride (210g, l.Smol) in water (500m1) was 
mixed with DCM (500m1) in a 3-neck 31 flask fitted with a mechanical stirrer and a 
nitrogen inlet tube and cooled to -15 °C (acetone/dry ice). A cold solution of sodium 
nitrite (124.5g. 1.8mol) in water (200m1) was added in one portion with stirring. The 
temperature was lowered to -20 °C and an ice cold solution of 5% (w/w) H 2 SO4 
(142.5g) was added dropwise over 30 minutes while keeping the temperature below - 
10°C. When all the acid solution had been added, the temperature was allowed to rise 
to 0°C(N.B. aqeous and DCM layers must be mixed thoroughly throughout). The 
reaction mixture was transferred to an ice cold 21 separating funnel. The yellow 
organic layer was run into an ice cold solution of 5% sodium carbonate (11) and the 
water layer was extracted once with DCM. The combined DCM and Na 2CO3 
portions were stirred until no more gas evolved. The two layers were separated and 
the water layer was extracted once with DCM. The organic layer was dried (MgSO4) 
and evaporated in vacua behind a screen. The yellow liquid, which was pure enough 
for the next step, was stored below 4 °C overnight in a well wrapped container. 
Yield 95-100%. 
Diazoacetic ester salt (43)45 
DMF (52.8g, 0.72mo1) was cooled by ice-salt bath under argon. Freshly distilled 
thionyl chloride (53m1, 0.72 mol) was added dropwise with stirring. When all the 
thionyl chloride had been added, the mixture was stirred at room temperature for 30 
minutes. The colourless gel was then evaporated in vacuo (via oil pump) for 2h 
(water bath —40°C), until a white solid was afforded (42). Care should be taken when 
open to the air. Assumed yield 100%. The white solid (42) was dissolved in A.R. 
chloroform (400m1) and cooled via ice salt bath. Ethyl diazoacetate (41), prepared 
above, was added dropwise under nitrogen keeping the temperature below 5 °C. 
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When the addition was complete, the reaction mixture was stirred at room 
temperature for 30 minutes then evaporated in vacuo. Fresh ether was added to the 
residue and the yellow solid afforded was filtered under nitrogen and washed with 
ether. The yellow solid was stored in a dessicator overnight and used in the next step. 
Yield 130g, 88%. 
1-Hydroxyl-4-ethoxy carbonyl-1,2,3-triazole (BOCt) (39)4.5 
NH2OH.HC1 (44g. 0.63mol) was dissolved in water (200m1), cooled via ice salt bath 
and the pH adjusted to —7-7.5 with solid Na 2CO3. The diazonium salt (43) (130g 
0.63mo1) was added as the solid while keeping the pH at 7-7.5 with 10% Na2CO3. 
The yellow product (44), which precipitated, was stirred for 5 minutes, filtered, 
washed with a little ice cold water and dissolved in AA chloroform- Any remaining 
water was removed by separation in a separating funnel followed by drying with 
MgSO4 . Alter filtration, acetic acid (0.5m1) was added to the chloroform solution to 
catalyse the cydisation and the solution was left at 4 °C until cycisation was complete. 
(Yellow colour fades but cycisation was confirmed by 111  NT4R). The chloroform 
solution was reduced in vacuo to a white solid which was filtered and washed with a 
little cold EtOAc. The filtrate was reduced to a small volume and stored at 4 °C until 
no more crystals formed. 
N.B. If an oil formed after evaporation of the chloroform solution, it was taken up 
into ethyl acetate then reduced in vacuo to remove any residual chloroform. More 
EtOAc was added and the concentrated solution was left at 4 °C to crystallise. 
Overall yield 22g, 50%. 
Mpt. 103-104 °C. CHN: (Found, C 38.43%, H 4.48%, N 26.77%, C51718N303 
Requires, C 38.2%, H 4.5%, N 26.8%. UV (DCM) A.,, = .234nm (E = 
224637dm3mo1'cni'). MS (MB) m/z = 158 (MW). HRMS (FAB) m/z = 
158.05779 (MW, C5H8N 303 Requires, 158.05657). IR (DCM) Om = 2000-3200 
(OH), 1730cm1 (C=O). 811 (200M4z, CDC1 3 ) 1.32 (3H, t, CH3), 4.31-4.4 (211, q, 
CH2), 8.08 (111, s, olefinic CH) and 10.43ppm (111, bs, OH). SC (CDC13, 50MHz) 
14.0 (CH3), 61.7 (CH2), 121.7 (olefinic C) and 159.2 ppm (C=O). 
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112N-Ala-X-Gly-OH for racemisation studies on HOCt 
The synthesis of each tripeptide was carried out on a 0.25mmoI scale using Fmoc-Gly 
loaded Wang resin (330mg, 0.25mmol, 0.87mmol/g). The peptides were synthesised 
manually using a sonic bath for agitation and each of the amino acids were single 
coupled as their active HOCt esters. The active esters were made by dissolving the 
amino acid (immol) and HOCt (157mg, Immol) in DMF (lOml) and sonicating this 
with DIC (1501J, immol) for 20 minutes at room temperature. The active ester was 
then added to the above resin, preswollen in DMIF (2m1), and the final mixture was 
sonicated for 2h. The coupling of each amino acid was confirmed by the UV 
monitoring method. The resin was capped using the normal acetic anhydride method 
and Fmoc deprotected using 20% piperidine/DMF before the next amino acid was 
coupled. All peptides were cleaved from the resin immediately using 95% TFAIH20 
(5m1) and EDT (lml). The cleavage mixture was reduced in vacuo via oil pump to an 
oil and the peptide was precipitated from ether. The ether was decanted off and the 
peptide was lyophilised and stored at 0 °C. 
X = Ala, Arg (Pmc), Asn, Asn (Mbh), Asn (Trt), Asp (Bu), Cys (Acm), Cys (Bu), 
Cys (Trt), Gin, GIn(Trt), Glu ('Bu), lie, Leu, Lys (Boc), Met, Phe, Pro, Ser (Bu), Thr 
(Bu), Tip, Tyr ('Bu), and Val. NIMIR studies, SH (360MHz, d 6DMSO), showed no 
evidence of racemisation for any of the above peptides. 
For X = His (Trt): The peptides containing His (Trt) were synthesised by automated 
SPPS and using the following combination of temperatures, activation times and 
amounts of HOCt 
Table 9 Raceniisation studies on His with HOCt 
Temperature (°C) Activation Time (mm) HOCt (mmol) 
ambient 15 1 
ambient 10 
ambient 5 1 
zero 15 1 
ambient 1 2 
ambient 1 3 
ambient 15 3 
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Pk determination of flOCt 
HOCt (0.1M) was titrated against NaOH (0.1M, 50m1). 34.3 ml of HOCt (5mmol) 
was required to reach the equivalence point which occurred at pH 8.15 as calculated 
from the titration curve. The K 6 value was calculated as 0.00727 and taking the 
negative of log10 of this value gave a Pka value for HOCt of 2.1. 
Chemical synthesis of dhEPO (50) 
The initial resin was Fmoc-Arg(Pmc)-Wang resin (I g, 0. Immol), using the method for 
a low loading. The protecting groups were as stated in the notes for Ser, Thr, Tyr 
Asp, His and Arg. lit protection was used for Asn, Cys and Gin and Boc protection 
on Lys. The amino acids were coupled using the HOCt method apart from histidine 
which was single coupled as the active HOBt ester. The last 20 residues, Lys(20)-
Ala( 1), were double coupled as their HOCt active esters. Approximately half the 
resin was removed after Ala(i 14) and the remaining resin was used to continue the 
synthesis until Val(46) when the remaining resin was removed. The sequence was 
continued to the end, simultaneously, from these two portions. Fmoc was not 
removed from the last amino acid, but the final resin functionality could not be 
determined due to the size of the protein and the initial low loading. The resins from 
the two syntheses were combined, filtered, washed with DMF, DCM then ether and 
dried in vacuo to an off white solid. 
Yield 2.2g. Amino acid analysis (48h hydrolysis), Asx 12 12.7, Thr 11 10.4, Ser 108.07, 
G1x 1 920.1, Pro89.4, Gly9ll.5, A1a 1920.3, Cys43.6, Val 11 10.4, Met 1 l.0, fle53.7, 
Leu2321.7, Tyr44.4, Phe43.8, His2l.8, Lysg8.7, Arg 13 12.9. 
lbfmoc loading (51) 
The resin bound protein (50) (2g) was given an additional capping (acetic 
anhydride/HOBt/DIEA), using DCM as the solvent and a sonicator for agitation. The 
resin was filtered, washed with DMF, I ,4-dioxane, DCM then ether and dried. The 
dried resin was sonicated in 20% piperidine/DMF for 15 minutes to remove the N-
terminal Fmoc group. The resin was filtered, washed with DMF, DCM, then ether 
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and dried. Thfinoc was loaded onto the peptide-resin, as described in the notes, and 
the resin was filtered, washed with copious DCM then ether and dried. 
Cleavage of Tbfmoc-dhEPO-resin (52) 
The resin bound Thflnoc-protein (51) (2g) was stirred in EDT (4m1), thioanisole 
(I ml), H20 (Imi) and phenol (1.5g) for 10 minutes. TFA (20m1) was added and the 
mixture was stitrred for 4.5h under thy nitrogen in the absence of light. The resin was 
filtered, washed with TFA (4m1) and reduced in vacuo to a yellow oil. The peptide 
was precipitated from ether, filtered and washed with ether. The protein was partially 
solubilised in 20% AcOH/H 20 (it is difficult to solubilise the protein in the aqueous 
systems required for freeze drying) and lyophilised in the absence of light to a white 
fluffy solid. 
Yield 914mg. HPLC (ABI, Aquapore RP300 C 4, 4.6 x 100, 7ji, A = H20, B = 
CH3CN, 0.1% TFA, lml/min. 30-80%B over 20 minutes. X 1 = 2 i4nm, X2 = 364nm). 
114 = 12 minutes, 60%B and 13 minutes, 62%B. Amino acid analysis (48h hydrolysis), 
Found, Asx12 12.7, Thr11 11.2, Ser 10 10.7, G1x 19 18.8, Pr077.3, G1y9 13.5, Ala, 920.1, 
Cys43.9, Va1 11 10.6, Met 1 l.0, 11e55.0, Leu2322.5, Tyr44.8, Phe44.1, His2 1.5, Lys88.8, 
Arg 13  12.9. 
Affinity purification on charcoal (53) 
Charcoal (5g) was washed with 10% pip eridine/6MGdniCl:isopropanol, 1:1, (lOOmI) 
followed by 6MGdin.Cl:isopropanol, 1:1, (9 x lOOmi). The crude Thfinoc-protein 
(52) (900mg, 50p.tniol) was solubilised in 6MGdm.Cl:isopropanol, 1:1, (60m1) and 
added to the freshly washed charcoal (5g). The mixture was vortexed for 10 minutes 
and centrifuged to a pellet. The supernatant was decanted and analysed by HPLC 
(ABI, Aquapore RP300 C 4, 100 x 4.6mm, 7M.  A = H20, B = CH3CN, 0.1% TFA, 
Imi/min. 30-800/oB over 20 minutes. ? = 214nm, A2 = 364nm). No absorbance was 
visible at 364nin; therefore it was assumed that all the Ththioc material had been 
adsorbed onto the charcoal. The charcoal was washed with 6MGdm.Cl:isopropanol 
1:1 until no absorbance at 214nm was visible by HPLC. The protein was cleaved 
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from Thfinoc by vortexing the charcoal with 10% piperidine/6M GcIm.Cl:isopropanol 
1:1 (2 x iSmi) for 10 minutes and then the mixture was centrifuged to a pellet. The 
supernatants from this were combined and reduced in vacuo to remove the 
isopropanol. The mixture was then acidified to pH 4 with AcOH and DTT (0. 1M) 
added. The solution was left at room temperature overnight. The solution (200ml) 
was dialysed (Spectra/Por 6 membrane, MWCO 10,000, supplied by Pierce and 
Warriner) against 6M 0dm. Cl for 2 days, changing the dialysis solution twice daily. 
The solution was removed from dialysis and concentrated to a volume of 40ml 
(Axnicon ultrafiltration, YM1O membrane, MWCO 10,000). 
HPLC (ABI, Aquapore RP300 C4, 100 x 4.6mm, 7p., A = H20, B = CH 3CN, 0.1% 
TFA, lmllmin. 30-80%B over 20 minutes. X = 214nm, X2 = 280nm). lk = 12 
minutes, 60%B. Amino acid analysis (48h hydrolysis), Found, Asx 12 12.9, Thr 11 9. 1, 
Ser 108.5, G1x 1925.2, Pro86.2, Gly912.8, Ala 1 919.4, Cys4/Val11I4.8 (not resolved), 
Met 1 I.5, 11e54.9, Leu2321.6, Tyr43.1, Phe44.2, His2 1.5, Lys88.7, Arg 13 9.6. 
FPLC gel filtration (54) 
Gel filtration was carried out on (53) using Superdex 75 HR26/60 column and 
eluting with 6M GdniCl over a column volume of ml. Fractions absorbing at 280nm 
were analysed by HPLC (ABI, Aquapore RP300 C4, 100 x 4.6mm, 7p., A = H20, B = 
CH3CN, 0.1% TFA, lml/min. 30-80%B over 20 minutes. X 1 = 214nm, X2 = 280nxn). 
Fractions 20-25 eluted with the correct retention (R = 11 minutes) time and were 
combined. Fractions 26-35 eluted with the correct retention time but were still 
slightly impure and therefore were concentrated, combined and reapplied to the 
column. All fractions with the correct retention time were combined and 
concentrated (MWCO 10,000) to a volume of 40m1. 
HPLC (ABI, Aquapore RP300 C4, 100 x 4.6mm, 	A = H20, B = CH3CN, 0.1% 
TFA, lnjlimin. 30-80%B over 20 minutes. X1 = 214nm, X2 = 280nm). R = 11 
minutes, 60%B. Amino acid analysis (48h hydrolysis), Found, Asx12 12.3, Thr 11 10.2, 
Ser 1 08.5, G1x 1 920.5, Pro88.3, G1y910.4, A1a 19 19.2, Cys40.1, Va1 11 12.2, Met 1 l.2, 
11e54.4, Leu2322.0, Tyr44.6, Phe44.1, 111522.7, Lys 88.7, Arg 13 12.9. 
109 
Chapter eight: Experimental 
Denaturing and folding 
The pH of the above solution (40m1) was adjusted to 8 by addition of Tris.HC1 
(50mM, p1-1. 8 37°C) and DTT (0. IM) added. The mixture was incubated at 37 °C for 
2h. UV analysis7 gave a protein content of approximately 12.6mg. The fully 
denatured dhEPO (12mg) was diluted to 500m] with Tris.HC1 (50mM, pH8, 5 °C), 
40tM CuSO4, 0.1% N-lauroyl sarkosine (folding buffer)" in 3M GdniCI, and the 
mixture was stirred overnight. A precipitate formed and was removed by 
centrifugation, denatured (as above) and stored in the freezer till required. The 
supernatant was dialysed against folding buffer in IM Gdm.C1 overnight. Again a 
precipitate formed and this was removed and treated as before. The supernatant was 
then dialysed (MWCO 10,000) against folding buffer only to give the folded protein 
(lmg/100m1). 
HPLC (ABI, Aquapore RP300 C 4, 100 x 4.6mm, 7t, A = H20, B = CH 3CN, 0.1% 
TEN, lml/min. 30-800/oB over 20 minutes. X 1 = 214nm, X2 = 280nm). R4 = ii 
minutes, 60%B. 
Tryptic digest 
3ml of denatured protein solution (approximately 0.2mg by UV analysis) was 
dialysed (MWCO 10,000) against Tris.HC1 (50mM, pH8, 37°C) in 3M GdLm.C1. 
Trypsin (5% w/v) was added and the mixture was incubated at 37 °C for 8h before a 
second aliquot of trypsin (5% w/v) was added. The resulting mixture was incubated 
at 37°C for 16h. 
HPLC (ABI Aquapore RP300 C18, 220 x 4.6mm, 7ji, A = 1120, B = CH 3CN, 0.1% 
TFA; lml/min. 10-90 %B over 30 minutes. ? = 214nm). R 1 = 10-22 minutes, 24-
60%B. MS (MALDI TOF) m/z = 2959 (MW, fragment 117-143, iC salt), 3807 
(MW, fragment 140-166, K salt), 4435 (MW, fragment 15-53, iC salt) and 
596 l(M}t, fragment 46-97, NC salt). 
I 
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Protein sequencing 8 
3m1 of denatured protein solution (approximately 0.2mg by IJV analysis) was dialysed 
(MWCO 10,000) against H 20 for 2 weeks changing dialysis solution twice daily. 
Some protein precipitated from solution and was solubilised in 100% CH 3CN, diluted 
with H20, combined with soluble material from the dialysis and lyophilised to an off 
white solid. 
Yield (---0.2mg). 
Sequencing analysis from N-terminus Found, residue(R), = Ala, 1(2 = Pro, 1(3 = Pro, 
It, = Arg, 1(5= Leu, 1(6 = Ile, R7 =n.d, R8 = Asp, 1(9 =?, R10 = ?, Ri I = Val, R12 = Len, 
= Glu, R14 = ?, R15 = Tyr, R16 = Len, R17 = Len, R18 = Glu, R 19 = Ma 
C8 1 5H 1 327N3440218S4, Requires, R 1 = Ma, 1(2 = Pro, R3 = Pro, K, = Arg, R5= Len, 1(6 = 
He, 1(7 = Cys, 1(6 = Asp, 1(9 = 8cr, R10 = Arg, R 11 = Val, R12 = Len, R13 = Glu, R14 = 
Arg, R15 = Tyr, 1(16 = Len, R17 = Leu, R 1 8 = Glu, R 19 = Ala. 
Copper[lysine] 2(84)1 
Lys.HC1 (83) (36.8g, 0.2mol) was dissolved in water (500m1). The solution was 
heated to 50°C before basic copper carbonate (66g. 0.3mol) was added. The resulting 
suspension was refluxed for 3h. The suspension was filtered while hot, to remove the 
excess copper carbonate, and washed with cold water (JOml). The filtrate was 
reduced in vacuo to yield the title compound as a blue solid. 
Yield 50g, 83%. 
42Butoxyphenylmethylacetate (86)' 
Methyl-4-hydroxyphenylacetate (85) (25g, 0. 15mol) was dissolved in DCM (120m1) 
in a 11 Buchi flask. The solution was cooled to -45 °C (acetone/dry ice bath) while 
stirring and isobutylene (-120m1) was condensed into the solution. Concentrated 
H2SO4 (2m1) was added and thoroughly mixed in. The flask was sealed and the 
solution was stirred at room temperature overnight behind a safety screen. The flask 
was cooled to -45 °C and carefully opened behind the screen. TEA (8ml) was added 
immediately (confirm alkaline pH) and the solution was allowed to warm to room 
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temperature while stirring. The solution was then warmed to 35 °C to release the 
excess isobutylene as a gas. The final solution was reduced in vacuo to an orange oil 
which was taken into DCM (lOOml). The organic solution was washed twice with 
10% sodium carbonate and once with dilute HCI (2H2). The organic layer was dried 
(MgSO4), filtered and reduced in vacuo to yield a pale yellow oil which was used 
without further purification. 
Yield 28g, 84%. 
Rj(hexane:EtOAc, 9:1) = 0.6. MS (MB) mlz = 223 (MW). JR (DCM) Um = 2978 
3034 (CH), 1746 (C0), 1508 and 1609cn1' (C=C). SM (CDCI3, 200MHz), 6.88-
7.39 (q, 41L aromatic CH), 3.79 (s, 31-I, OCH3), 3.64 (s, 2H, CH2), 1.32ppm (s, 9H, 
'Bu). SC (CDCI 3, , 50MTrIz), 172.18 (C=O), 154.24 (C-O), 129.55 and 124.09 (CH x 
4), 128.62 (quaternary aromatic C-CH2), 53.29 (OCH3), 40.31 (CH2), 29.29ppm 
('Bu). 
42Butoxyphenyl acetic acid (87)' 
4-'Butoxyphenylmethylacetate (86) (28g, 0. 13mol) was taken into acetone:H 20 
(500m1, 4:1). The solution was cooled to 0 °C and lithium hydroxide monohydrate 
(10.53g, 0.25mmol) in H20 (168m1) was added. The solution was stirred for 4h 
before the acetone was removed in vacuo. The resulting solution was washed with 
ethyl acetate, to remove any unreacted starting material, and the pH was adjusted to 
3.5 by slow addition of 2M HC1. The product precipitated from solution and was 
extracted from the aqueous layer with ethyl acetate, dried (Mg504) and reduced in 
vacuo to yield the title compound as shiny white needles which were recrystallised 
from ether, filtered and washed with a little cold hexane. 
Yield 20g, 80%. 
Mpt. 77-79°C. Rf (hexane:EtOAc, 9:1) = 0.14. CH: Found, C 68.94%, H 7.78% 
(C12H1603 Requires, C 69.23%, H 7.69%). MS (El) niilz = 207.9. ilk (nujol mull), 
U max = 2670-2724 (CH), 1703 (C=O), 1605 and 1508cn1' (C=C). SH (CDC13, 
200MHz), 9.09 (brs, 11-1, OH), 6.95-7.19 (q, 4H, aromatic CH), 3.59 (s, 2H, C112), 
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1.33ppm (s, 91-1, 'Bu). SC (CDC13, 50Mhz), 177.86 (CO), 154.33 (C-O), 129.71 
and 124.14 (CH x 4), 127.99 (quaternary aromatic C), 40.26 (CH2), 29.33ppm (Bu). 
CopperN-4-'butoxyphenyIacetyI Iysinej2 (89)1 
4-'Butoxyphenylacetic acid (87) (lOg, 0.05mol) was dissolved in 1,4-dioxane (80m1) 
and phenylphthalene (1 drop) was added. The solution was titrated with NaOH (2M), 
40m] being required to turn the indicator pink. The solution was reduced in vacuo to 
a white solid which was dried in a dessicator (10.3g). The dry sodium salt (lOg, 
0.04mol) was stirred in sodium dried benzene (40m1) and freshly distilled oxalyl 
chloride (3.8m1, 0.04mol) followed by DMF (0.1ml) were added. The mixture was 
stirred for 3h and the solution was reduced in vacuo to yield the acid chloride (88). 
The acid chloride (8g, 0.03mol) was dissolved in 1,4-dioxane (20m1) and added 
slowly, over a period of 2h, to a solution of copper[lysine] 2 (6g. 0.02mol) in H20 
(SOml) while keeping the pH at 10 with 10% sodium carbonate. The product 
precipitated from solution as the reaction progressed. The product was filtered, 
washed with H20 and dried to yield the title compound as a pale blue solid (89). 
Yield 8.48g, 27%. 
W-4ButoxyphenyIacetyl lysine (90) 
Dry, finely powdered copper[W-4-'butoxyphenylacetyl-lysine] 2 (89) (1.49g, 
2.03mmo1) was suspended in a stirred solution of EDTA disodium salt (0.77g. 
2.03mmoI) in H20 (105m1). The suspension was stirred at room temperature 
overnight. The suspension was filtered and the white solid was washed with H 20 and 
left to dry. 
Yield 0.33g, 48% 
Mpt. 215T. CHN: Found, C 64.36%, H 8.72%, N 8.26%, (C 181128N204 Requires, C 
64.3%, H 8.3%, N 83%). MS (FAB), m/z = 337 (MW), HRMS (FAB), m/z = 
337.2 1273 (MI-C C18H28N204 Requires, 337.21272). ilk (nujol mull), Um = 3316 
(NH). 1739 and 1646 (C=O), 1589cm' (C=C). SH (d 6DMSO, 200MHz), 6.77-7.02 
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(q, 4H, aromatic CH), 2.91-2.95 (d, 21-1, C112CH), 2.61-2.64 (t, 11-I, "CH), 1.2-1.34 
(in, 81-, C112 x 4), 1. l4ppm (s, 9H, 'Bu). SC (d 6DMSO, 50MHz), 183.42 and 174.12 
(C0), 152.54 (C-O), 131.13 (quaternary aromatic C), 124.67 and 129.57 (aromatic 
CH), 55.71 ("CH), 39.12, 34.39, 28.06 and 22.22 (CH2), 27.73ppm (Bu). 
N"-9-Fluorenylmethoxycarbonyl-N °-4-'butoxyphenylacetyl lysine (91) 
W-4-tbutoxyphenylacetyl-lysine (90) (1.76g. 5.2mmol) was suspended in H20 (30m1). 
A solution of TEA (1. imI, 0.79mmol) in 1,4-dioxane (30m1) followed by solid Fmoc-
ONSu (1.68g, Smmol) were added. The mixture was stirred overnight then diluted 
with 1120 and acidified to pH2 with 1M HC1. The product which precipitated was 
extracted with EtOAc, washed with H 20, dried (MgSO4) and reduced in vacuo to an 
oil. The oil was crystallised from EtOAc/hexane to yield the title compound (91) as a 
white solid which was filtered and dried. 
Yield 0.2g, 7.2%. 
Mpt. 105 °C. Cl-IN: Found, C 70.72%, H 6.86%, N 4.47% (C33H38N206 Requires, C 
71%, H 6.8%, N 5%). UV ?cmax (MeOH) 253 (E = 17232), 271 (c = 5108), 290nm (E 
= 6043dm3mor 1 cni 1 ). MS (FAR), m/z = 559 (M}C). FIRMS (FAB), m/z = 
55918083, (C33H33N 206 Requires, 559.28079). Ut (bromoform mull), Um = 3388 
3413 (NH), 2823-3040 (CH), 1739, 1718 and 1655 (C=0), 1509cm 4 (C=C). 511 
(dDMS0, 200MHz), 6.85-8.07 (m, 121-f, aromatic CH), 4.2-4.31 (in, 3H, acIt  "NH, 
GNU), 3.96-3.98 (m, 111, fluorenyl CH), 3.01-3.1 (d, 211, fluorenyl CH2), 1.36-1.67 
(in, 811, CH2 lysine), 1.21 (s, 9H, 'Bu). SC (d 6DMSO, 50Mhz), 174.14, 170.22 and 
169.07 (C0), 156.3 (quaternary aromatic C-0), 143.94 and 156.3 (quaternary 
fluorenyl C), 130.22 (quaternary aromatic C), 120.25, 121.51, 123.64, 125.42, 127.2, 
127.78, 129.56 and 130.08 (aromatic CH), 65.72 (fluorenyl Cl-I2), 53.89 ("CH), 46.77 
(fluorenyiCH), 23.23, 30.54, 38.35 and 41.79 (Cl-I2, lysine), 28.65ppm(Bu). 
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4-Copper[N°-4-methoxyphenylacetyl lysine] 2 
4-Methoxyphenylacetic acid (8g, 0.05mol) was suspended in sodium dried benzene 
(40m1) and freshly distilled oxalyl chloride (3.8m1, 0.04mol) followed by DMF (0.lml) 
were added. The mixture was stirred for 3h and the solution was reduced in vacuo. 
The acid chloride (8g. 0.03mol) was dissolved in 1,4-dioxane (20ml) and added 
slowly, over a period of 2h, to a solution of copper[lysine] 2 (6g. 1 7mmol) in H20 
(50m1) while keeping the pH at 10 with 10% sodium carbonate. The product 
precipitated from solution as the reaction progressed. The product was filtered, 
washed with 1120 and dried to yield the title compound as a pale blue solid. 
Yield 6.9g, 25%. 
N°-4-Methoxyphenylacetyl lysine 
Dry, finely powdered copper[W-4-methoxyphenylacetyl lysine] 2 (6g, 9.24mmol) was 
suspended in a stirred solution of EDTA disodium salt (3.4g. 9.24mmol) in 1120 
(600m1). The suspension was sonicated for two days. The suspension was filtered 
and the white solid was washed with H 20 and left to dry. 
Yield 3.6g, 66.5% 
Mpt. 241-242°C. CFIN: (Found, C 61.2%, H 7.53%, N 9.52%, (C 1517123N204, 
Requires, C 61.16%, H 7.63%, N 9.39%). MS (FAB), m/z = 295 (MW), HRMS 
(FAB), nilz = 295.16562 (MI? C 1517123N204, Requires, 295.16578). IR (bromoform 
mull), u,, = 3721 (NH). 1668 and 1635 (C=0), 1540 and 1513cm 1 (C=C). SH 
(d6DMSO, 200MHz), 6.69-7.09 (q, 411, aromatic CH), 3.58 (s, 3K CI-1 3), 2.85-2.9 
(in, 311, aCH  and CH2), 1.31-1.69 (in, 81-1, CH 2 lysine). SC (d'DMSO, 50MHz), 
183.42 and 174.12 (C=0), 156.91 (quaternary aromatic C-0), 129.66 (quaternary 
aromatic C), 113.86 and 130.01 (aromatic CH), 55.33 ("CH), 40.06, 34.23, 31.45 and 
22.04 (CH2. lysine), 26.33ppm(OCH3 ). 
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N"-9-Fluorenylmethoxycarbonyl-N °-4-methoxyphenylacetyl lysine (93) 
Nv4Methoxyphenylacetyllysine  (3g. 10.2mmol) was suspended in H20 (56m1). A 
solution of TEA (2. 14m1, 15.6mmol) in 1,4-dioxane (56ml) followed by solid 9-
fluorenylmethylsuccinimidyl carbonate (3.2g. 9.7mmol) were added. The mixture was 
stirred overnight at room temperature. The mixture was diluted with H20 (lOOmi) 
and acidified to p112 with 2M HC1. The product which precipitated was extracted 
with EtOAc, washed with H20, dried (MgSO4) and reduced in vacuo to a clear oil. 
The product was crystallised from EtOAc/ether to yield the title compound as a white 
solid which was filtered and dried. 
Yield 3.2g, 60.7%. 
Mpt. 143-144°C. CHN: Found, C 69.5%, H 6.35%, N 5.53% (C31713iN206 Requires, 
C 69.77%, H 6.01%, N 5.43%). UV X, (Me011) 255 (c = 16466), 279 (c = 4345), 
291nm(c = 5088dm3moF'cm 1 ). MS (FAB), mhz = 517 (MW). HRMS (FAR), mhz = 
5 17.23388, (MW, C301-13 1N206, Requires, 517.23384). IR (bromoform mull), Um = 
3336-3418 (NH), 2823-3040 (CH), 1743, 1711 and 1693 (C=O), 1509cm 1 (C=C). 
SR (d6DMSO, 200MHz), 6.76-7.77 (m, 12H, aromatic CH), 5.7-5.75 (m, NH x 2), 
4.15-4.43 (m, 311, "CH and CH 2), 3.73 (s, 31-, CR 3 ), 3.44-3.52 (t, 2H, C112), 1.11- 
1.78 (m, 8H, CH2 lysine). SC (d6DMSO, 50MHz), 174.59, 172.88 and 158.78 
(C=O), 156.13 (quaternary aromatic C-O), 143.75 and 143.57 (quaternary fluorenyl 
C), 125.05 (quaternary aromatic C), 119.82, 126.05, 126.95, 127.78 and 127.56 
(aromatic CH), 66.9 (fluorenyl CE12), 55.14 ("CH, lysine), 53.41 (fluorenyl CH), 
42.39 (CR2), 46.96 (CH3), 21.85, 28.71, 31.57 and 39.07ppm (CR2, lysine). 
!l-Phe-Gly-Lys(Mepa)-Ala-GIy-OH 
The initial resin was Fmoc-Gly-Wang resin (0.4g, 0.25mmol, 0.63mmol/g). The 
amino acids were coupled using the HOBt method and lysine was incorporated as the 
4-methoxyphenylacetamidomethyl (Mepa) derivative. The peptide-resin was cleaved 
with a solution of TFA (9.5ml) and H20 (0.5m1) for lh and the resin was removed by 
filtration. The resin was washed with TFA (2m1) and the filtrate was reduced in 
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vacuo to an oil. The peptide was precipitated from ether, filtered and washed with 
ether. The peptide was dissolved in 20% acetic acid/H20 and lyophilised to yield the 
title compound as a white fluffy solid. 
Yield 13 5mg, 86%. 
HPLC (Vydac C18, 250 x 2.6mm, Sj.x, A = H20, B = CH3CN, 0.1% TFA; imi/min. 
10-90 %B over 30 minutes. X = 214mn). K = 13 minutes, 43%B. MS (FAll) m/z = 
627 (MW). 
H-Phe-GIy-Lys(Phenac)-Ala-GIy-OH 
The initial resin was Fmoc-Gly loaded-resin (0.45g. 0.25mmol, 0.55mmol/g). The 
amino acids were coupled using the HOBt method and lysine was protected as its 
phenylacetamidomethyl (Phenac) derivative. The peptide-resin was cleaved with a 
solution of TFA (9.5m1) and 1120 (0.5m1) for lh and the resin was removed by 
filtration. The resin was washed with TFA (2m1) and the filtrate was reduced in 
vacuo to an oil. The peptide was precipitated from ether, filtered and washed with 
ether. The peptide was taken into 20% acetic acid/H 20 and lyophilised to yield the 
title compound as a white fluffy solid. 
Yield 130mg, 87%. 
HPLC (Vydac C18, 250 x 2.6mm, 5R.  A = H20, B = CH3CN, 0.1% TFA; lml/min. 
10-90 %B over 30 minutes. X = 214nm). K = 11 minutes, 37%B. MS (FAB) m/z = 
597 (MIT). 
H-Phe-GIy-Lys-Ala-Gly-OH 
Route A: from H-Phe-Gly-Lys(Mepa)-Ala-Gly-OH. 
Route B: from H-Phe-Gly-Lys(Phenac)-Ala-GIy-OH. 
As a general method, a 12.7mg (0.2mmol) portion of each peptide was added to 
Tris.HC1 buffer (50 mM, 6ml, pH 8.1). Resin bound penicillin acylase (60mg, 
E.C.3.5.1.11, 1325M.units/Kg, supplied by SmithKline Beecham Pharmaceuticals 
Ltd) was added and the mixture was allowed to mix gently whilst incubating at 37 °C. 
The progress of each reaction was monitored by ITIPLC (Vydac C13, 250 x 2.6mm, 
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5)1, A = H20, B = CH3CN, 0.1% TEA; lmL/min. 10-40 %B over 30 minutes. A = 
214nm). Route A took 191h for flill deprotection while route B took only 51h. On 
completion of the reaction the resin bound enzyme was removed by filtration and 
washed with water. The deprotected peptides were isolated by analytical HPLC and 
lyophilised to yield the title compound as a white fluffy solid. 
Yield 5mg, 52%. 
HPLC (Vydac C18, 250 x 2.6mm, 5)1, A = H20, B = CH3CN, 0.1% TEA; imi/min. 
10-40 %B over 30 minutes. X = 2l4nm). R, = 5 minutes, 21%B. MS (LAB), m/z = 
479 (MW). HRMS (FAB), m/z = 479.26184 (MW, C 22H35N606 Requires, 
479.26179). Amino acid analysis (12h hydrolysis): G1y 22.1, Ma,1.1, Phe 1 l.0, 
Lys, 1.2. 
H-Fhe-GIy-Lys(llopa)-Ala-GIy-OH 
The initial resin was Fmoc-Gly-Wang resin (0.53g. 0.25mmol, 0.48mmolIg). The 
amino acids were coupled using the HOBt method. Lysine was protected as the 4-
methoxyphenylacetamidomethyl derivative. Thflnoc was loaded onto the completed 
resin bound peptide (0.58g), as described in the notes at the beginning of this chapter 
and a Thfinoc loading test gave a final resin functionality of 0.354mmolIg. The 
Thflnoc loaded peptide-resin (0.3g, 0. l2mxnol) was stirred in thioanisole (0.5ml), 
TEMSA (0.9m1) and TEA (2m1), in the absence of light, for 20 minutes at 0 °C then 
for 2h at room temperature. The cleaved resin was removed by filtration and washed 
with 70% CH3CN/H20. The filtrate was applied to a column of PGC and the eluate 
was reapplied 3 times to ensure 100% adsorption of the Thfinoc-peptide. The column 
was washed copiously with 70% CH3CNIH20. The peptide was cleaved from 
Thflnoc by applying 10% piperidine in 70%CH3CNJH20 (50m1) to the column. The 
filtrate was neutralised by addition of AcOH and reduced in vacuo. The title 
compound was isolated by HPLC (ABI Aquapore RP300 C18, 250 x 10mm, 20)1, A = 
H20, B = CH3CN, 0.1% TFA; Smllmin. 10-40%B over 40 minutes. X = 214nm. R4 
= 9 minutes, 30%B) and lyophilised to yield a white fluffy solid. 
Yield 32mg, 21%. 
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HPLC (Vydac C 18,250 x 2.6mm, 5M  A = H20, B = CH3CN, 0.1% TFA; imI/min. 0-
30 %B over 20 minutes. X = 214nni). R = 9 minutes, 22%B. MS (FAB), m/z = 615 
(MW). FIRMS (FAB), mlz = 613.29858 (MW, C 30H41 N608 Requires, 613.29856). 
Amino acid analysis (12h hydrolysis): GlY22.0,  Ala1 1.2, Phe 1 1.0, Lys1 1.0. 
Methyl 2-bromobenzoate (96)23 
N-Bromosuccinimide (65.0g, 0.37mo1) and a catalytic amount of dibenzoylperoxide 
were added to a solution of freshly distilled methyl 2-methyl-benzoate (50.0g, 
0.33mo1) in methyl formate (500m1). The mixture was heated at 50 °C under reflux 
for 2h while irradiating with a halogen lamp (500W), switching the lamp off 
periodically to control the vigour of the reaction. Hexane (11) was added and the 
precipitate was removed by filtration. The filtrate was reduced in vacuo to yield the 
title compound as a yellow oil which was used without further purification. 
Yield 72.8g, 87.5%. 
2-(Methoxycarbonyl)benzyltriphenylphosphonium bromide (97)2.3 
Methyl 2-bromobenzoate (96) (72.8g, 0.32mo1) was dissolved in toluene (500m1) 
together with triphenylphosphine (66.1g, 0.29mo1) and the solution was stirred over 
the weekend. A white precipitate formed which was filtered, washed with toluene 
and dried in a dessicator to yield the title compound as a white solid. 
Yield 100.75g, 64.3%. 
Mpt. 234-235°C (lit3 230-235 0C). 
2-(3'-Methoxyphenethenyl) benzoic acid (98)2.3 
2-(Methoxycarbonyl)benzyltriphenylphosphonium bromide (97) (100.75g, 0.2 imol) 
and m-anisaldehyde (29.95g, 0.22mo1) were stirred in 1,4-dioxane (350ml) under an 
atmosphere of dry nitrogen. A solution of DBU.HBr (32.75g. 0.215mol) in 1,4-
dioxane (50m1) was added and the mixture was stirred at 50 °C for 3h. After cooling, 
the DBU.HBr which precipitated was filtered and washed with 1,4-dioxane (200m1). 
Water (160m1) followed by 2M NaOH (250m1) were added to the filtrate and the 
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mixture was heated under reflux for 45 mins. The solution was concentrated in 
vacuo, 1120 (11) added and the yellow precipitate which formed was filtered and 
washed with H20 (200m1). The combined filtrate was washed with ethyl acetate (2 x 
500m1) and ice added to the aqueous layer. The aqueous layer was acidified to pHi 
with 2M HC1 and a precipitate formed. The precipitate was filtered, taken up into 
ether, dried (MgSO4) and the solvent was removed in vacuo to give the title 
compound as a cream solid. 
Yield 41.82g, 78.4%. 
Mpt. 110°C. Rf = 0.33 (6:4 EtOAc/hexane). CH: (Found, C 74.56%, II 5.6%. 
C 16H1403 Requires, C 75.6%, H 5.5%). UV 4. (MeOH) = 292.6 (e = 26746.2), 
209.8 (c = 25069.8), 257.8nm (s = 8915.4dm3moi'cm'). MS (FAB), m/z = 255 
(M111). HRMS(FAB), m/z= 255.10212(MH*,  C 1 6H 1403 Requires, 255.10211). IR 
(bromoform mull), Um = 2750-3030 (OH), 1690 (C=O), 1501, 1580, 1597cm' 
(C=C). 611 (CDCI3, 200MHz) 9.3 (1H, br s, OH), 6.57-8.13 (IOH, m, 8 aromatic CH 
and 2 olefinic CH), 3.82 and 3.55ppm (3H, s, OC113 cis/trans isomers). SC (CDC1 3, 
50MT4z) 172.4 and 171.9 (COOH, cis/trans isomers), 159.6 and158.9 (quaternary 
aromatic COCH3, cis/trans isomers), 112-140 (aromatic CH and olefinic CH), 55.0 
and 54.7ppm (CH3 cis/trans isomers). 
2-(3'-Methoxyphenethyl)benzoic acid (99)23 
2-(3'-Methoxyphenethenyl)benzoic acid (98) (41.75g, 0. l6mol) was dissolved in 
methanol (500m1) and added to 10% PdIC (2.5g). The resulting mixture was stirred 
under an atmosphere of dry nitrogen until all acid had dissolved. The mixture was 
hydrogenated overnight and ethyl acetate was added to dissolve the precipitated 
product. The mixture was filtered through celite to remove the catalyst and this was 
washed with ethyl acetate to recover any undissolved product. Ethyl acetate was 
removed in vacuo and the residue was recrystaffised from methanol to give the title 
compound as a white solid. 
Yield 25.46g, 60.64%. 
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Mpt. 119-121°C (lit.' 120-120.5 0C), CH: (Found, C 75.04%, H 6.22%. C16H1603 
Requires, C 75%, H 6.25%. UV X (MeOH) 280 (c = 5180), 273 (E = 4970), 
209nm (s = 35200dm3moF'cm'). MS (El), m/z = 256.9, 238.9 and 121. JR 
(bromoform mull), U rna = 2750-3022 (OH), 1693 (C=O), 1495, 1581, 1595cn1' 
(C=C). 6H (200MH7, &DMSO) 11.8 (1H, br s, OH), 6.74-8.14 (81-I, m, aromatic 
CH), 3.78 and 3.84 (31-f, s, OCH 3, two conformations), 2.9-3.59ppm (41-1, m, CH2 x 
2). SC (50MHz, d6DMSO) 173.31 and 173.17 (C=O, two conformations), 159.7 and 
159.44 (quaternary aromatic COCH3,two conformations), 144.7, 143.4, 140.0 and 
138.64 (quarternary aromatic C), 111.42-133.04 (aromatic CH), 55.09 and 54.95 
(CH3, two conformations), 38.05 (CH 2) and 36.9 lppm (CH 2 ). 
2-Hydroxydibenzo [a,d] cycloheptadien-5-one (100)2.3 
2-(3'-Methoxyphenethyl)benzoic acid (99) (25.Og, 0. imol) was taken in dry benzene 
(60m1) and oxalyl chloride (17.1ml, 0.2mol) followed by DMF (0.lml) were added 
while the mixture was cooled on an ice/salt bath. The mixture was stirred at room 
temperature under an atmosphere of dry nitrogen for 2h, after which time the acid had 
dissolved and the gas evolution had ceased. Excess oxalyl chloride and benzene were 
removed in vacuo and the residue taken up in sodium dried benzene (lOOnil). A 
suspension of fresh aluminium chloride (37.02g. 0.28mo1) was slowly added to this 
whilst cooling and stirring on an ice/salt bath. The mixture was heated under reflux 
for 30min then cooled via ice/salt bath before slowly adding 2M HC1 (250m1) with 
mixing. Ether was added to dissolve any precipitated product and a black insoluble 
solid was removed by filtration. The etherial extract was washed with water, dried 
(MgSO4) and the solvent removed in vacua The residue was recrystaffised from 
ether/n-hexane to yield the title compound as pale needles. 
Yield 18.2g, 91%. 
Mpt. 141-142°C (lit. 3 141-141.5 0C). CH: (Found, C 80.4%, H 5.38%, C 1 5H1202 
Requires, C 80.4%, H 5.4%). UV X,,,,,, (MeOH) = 302 (c = 16700), 240 (E = 12300), 
208nm ( = 28800dm3mo1'cm 4). MS (El), m/z = 224, 196, 181 and 165. lIt 
(CH202), Uma,c = 3570 (OH), 1632 (C=O), 1495, 1567, 1603cm' (C=C). SH 
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(200MHz, CDC13), 8.14-6.82(71-1, m, aromatic CH), 7.65 (1H, s, OH), 3.12ppm(41-1, 
s, CH2 x 2). SC (50MHz, CDC13) 192.2 (quaternary aromatic CO), 162.0 (quaternary 
aromatic, C=O), 145.8, 141.9 and 139.2 (quaternary aromatic C), 134.0, 132.2, 
130.5, 129.0, 126.7, 116.1 and 114.4 (aromatic CH), 35.6 (CH2), 34.4ppm(CH2). 
Dibenzo Ia,dJ cycloheptadien-5-one-(2-oxyphenylacetate) (101) 2.3 
2-Hydroxydibenzo[a,d]cycloheptadien-5-one (100) (3.0g, 13.4mmol) was taken in 
acetone (100m1) along with anhydrous potassium carbonate (18.5g, 134.Ommol) and 
benzyl-2-bromoacetate (3.09g. 13.5mmol). The resulting mixture was stirred at room 
temperature overnight. The excess potassium carbonate was removed via filtration 
and the filtrate concentrated in vacuo. The residue was taken into ethyl acetate 
(loom!), washed with a fresh solution of 10% sodium carbonate (3 x 25m1) then H 20 
(25m1). The organic layer was dried (MgSO 4 ) and the solvent was removed in vacuo 
to yield the title compound as a white solid which was washed with a little ether. 
Yield 3.36g, 67.4%. 
Mpt. 79-80°C (lit. 3 81.5-82°C). CH: (Found, C 77.76%, H 5.39%, C221-11904 
Requires, C 77.4%, H 5.4%). MS (FAB), m/z = 373 (MIII'), FIRMS (FAB), m/z = 
373.14399 (MW C22H 1 904 Requires, 373.14397). IR (bromoform mull), Um = 
2625-3020 (aromatic CH and CH2), 1767 (CO 3 ester), 1633 (C=O,. ketone), 1495, 
1595, 1598cm' (C=C). SH (CDC1 3, 200M-1z), 6.68-8.13 (121-1, m, aromatic CH), 
5.23 (211, s, OCH2CO2), 4.71 (21-1, s, CH2Ph), 3.1 2ppm (41-, s, CF! 2 x 2). SC (CDCI3, 
50MHz), 193.13 (quaternary aromatic CO), 168.05 (C=O, ketone), 160.05 (C=0, 
ester), 144.93, 141.45, 138.74 and 131.64 (quaternary aromatic C), 134.83, 133.64, 
132.02, 130.50, 128.36, 126.50, 114.94 and 112.36 (aromatic CH), 66.99, 64.90, 
35.55 and 34.50ppm(4 x CH2). 
Dibcnzola,dl cycloheptadien-5-one-(2-Oxyacetic acid) (102)2.3 
Dibenzo[a,d]cycloheptadien-5-one-(2-oxyphenylacetate) (101) (3.35g, 9.0 lmmol) 
was dissolved in methanol (45ml) along with 2M NaOH (9.2m1). The mixture was 
heated under reflux for Ih before removing the methanol in vacuo. Water (50m1) was 
122 
Chapter eight: Experimental 
added to the residue followed by ice and the mixture was acidified to pHi with 2M 
HC1. The aqueous layer was extracted with ethyl acetate (3 x 25m1) and the organic 
layer dried (MgSO4). Ethyl acetate was removed in vacuo to a white solid which was 
washed with a little cold methanol to yield the title compound as a white solid. 
Yield 2.31g, 91%. 
Mpt. 163-164°C (lit. 3 164-165 0C). CH: (Found, C 72.42%, H 4.96%, C 1 7H1404 
Requires, C 72.3%, H 4.96%). MS (El), m/z = 282, 195, 73. ilk (bromoform mull), 
Umax = 2750-3032 (aromatic CH and CH 2), 1729 (C=O, acid), 1646 (C=O, ketone), 
1502, 1604cn1' (C=C). SH (CDC1 3, 200MHz), 6.31-7.65 (71-I, m, aromatic CH), 
4.23 (2H, s, CH2), 2.72ppm (411, s, CH2 x 2). 8C (CDCI3, 50Mhz), 191.79 (CO, 
ketone), 168.97 (C=O, acid), 159.9 (quaternary aromatic CO), 144.0, 140.48, 137.66 
and 130.08 (quaternary aromatic C), 132.37, 131.07, 129.25, 127.78, 125.42, 113.81 
and 111.55 (aromatic CH), 63.61 (CH2), 34.53 and 33.4ppm (2 x CH 2). 
flibenzo Ia,d] cycloheptadien-5-one-(2-oxyacetate-X-PAM) resin 
(X = Ala or Leu or Val) 
Boc-X-PAM-resin (104) (0.82g, 0.71mmolIg/NT-1 2, 0.58mmol) was stirred 
mechanically in 95% TFAIH20 (lOmi) under an atmosphere of dry nitrogen for 30 
minutes to remove the Boc group. The resin was filtered, washed with TFA (2m1), 
DCM, DWA (2m1), copious DCM then ether and left to dry in vacuo (0.73g). 
Dibenzo[a, d]cycloheptan-5-one-(2-oxyacetic acid) (102) (1.35g, 4. 8mmol) and HOBt 
(9.6m1, 4.8mmol) were dissolved in DMIF and to this DIC (460.2p1, 2.95mmo1) was 
added. The mixture was sonicated for 30 minutes at room temperature before adding 
it to the above resin (1.4g, 0.56mmol/gINH2, 0.78mmol) preswollen in DMF along 
with 2,6-lutidine (1. 12m1, 9.6mmo1). The final mixture was stirred (mechanical 
stirrer) at room temperature overnight under an atmosphere of dry nitrogen after 
which time the resin showed only pale blue to the Kaiser test. The resin was filtered, 
washed with DMF, DCM then ether and dried in vacuo to yield 1.42g of product. 
Quantitative Kaiser test showed only 0.002mmoJIg of unreacted amine. 
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IR (KBr disc) Om = 3315-3426 (NH), 2080-3840 (aromatic CH and CH 2), 1741 
(C=O, ester), 1685 (CO 3 amide 1), 1655 (C=O, amide II), 1639 (C=O, ketone), 
1598cn1'(C=C). 
Dibenzo[a,dlcycloheptadien-5-oI-(2-oxyacetate-X-PAM) resin 
Dibeazo[a,djcycloheptadien-5-one-(2-oxyacetate-X-PAM) resin (1.0g, 0. S6mmol) 
was preswollen in sodium dried TI-IF and LiBH4 (0.01g. O.Sbmmol) was added. The 
resulting mixture was stirred mechanically for lh at room temperature. The reaction 
was monitored by IR (KBr disc) and was considered to be complete when the 
carbonyl stretch at 1645cn7 1 corresponding to the ketone functionality had 
disappeared. The resin was filtered, washed with THF, THF/methanol (1:1), 
THF/acetone (1:1), 1mM HC1 in TI-IF then ether and was allowed to dry in vacua 
(0.8g). 
JR (KBr disc) o. = 3422-3480 (NH), 2840-3080 (aromatic CH and Cl-i 2), 1742 
(CO, ester), 1686 (CO 3 amide I), 1654 (CO 3 amide I), 1600cni' (CC). 
Dibenzo [a,dlcycloheptadien-5-Fmoc-amino-(2-oxyacetate-X-PAM) resin 
(amide PAM resin) 
Dibenzo[a, d]cycloheptadien-5-ol-(2-oxyacetate-X-PAM) resin (0.4g, 0.22mmol) was 
preswollen in a minimum amount of 1,4-dioxane and stirred mechanically under an 
atmosphere of dry nitrogen. 9-Fluorenylmethylcarbamate (prepared by the method of 
Carpino) (0.32g, 1.34mmol) was dissolved in a minimum amount of 1,4-dioxane and 
added to the resin through a cotton wool filter to remove any insoluble material. 
Benzene suiphonic acid was added to the mixture while stirring until the pH had been 
adjusted to 3 and the mixture was stirred for oh. The resin was filtered, washed with 
1,4-dioxane followed by ether and dried in vacuo (0.44g, functionality of resin 
0.2 lnxmol/g by Fmoc loading test (Section 9.1)) 
IR (KBr disc), u,,. = 3325-3426 (NH), 2840-3080 (aromatic CH and CH2), 1737 
(CO, ester), 1720 (C=O, amide III), 1685 (C=O, amide II), 1655 (CO 3 amide I), 
1600cm 1  (C=C). UV (20% piperidinelDMF) X. = 300 and 290nni. 
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Dibenzo[a,dI cycloheptadien-5-Boc-hydrazine-(2-oxyacetate-X-PAM) resin 
(Soc hydrazide PAM resin) 
Dibenzo[a,d]cycloheptadien-5-ol-(2-oxyacetate-X-PAM) resin (2g, 1.1 7mmol) was 
preswollen in DCM (80nil) and to this t-butyloxycarbonyl carbazate (1.08g. 
8. I7mmol) along with benzene suiphonic acid (0. lg, 0.58mmol) were added. The 
resulting mixture was refluxed under dry nitrogen for 6h. The mixture was allowed to 
cool and the resin was filtered, washed with DCM, DMIF then ether and dried in 
vacuo (1.86g). 
JR (KBr disc) u, = 3317-3423 (NH), 2840-3080 (aromatic CH and CH2), 1741 
(CO3 ester), 1716 (CO 3 carbamate), 1655 (C=O, amide I), 1685 (C=O, amide II), 
1600cm' (C=C). 
Fmoc Gly hydrazide PAM resin 
To Fmoc-Gly-01-1 (1.49g, Smmoi) SSTCd in DCM (30rn1) at 0 °C was added oxalyl 
chloride (0.86m1, lOmmol) and DMF (lOpi). The mixture was stirred at room 
temperature for 30 minutes at which time gas evolution had ceased and reactants were 
completely in solution. Excess oxalyl chloride was removed by rotary evaporation 
and the residue was redissolved in DCM (lOmi) and added to Boc hydrazide PAM 
resin (Ig, 0.527mmo1) preswollen in DCM (20ml) and pyridine (5m!). The mixture 
was refluxed under nitrogen for 4h and the resin isolated by filtration. The resin was 
washed with DCM, DMF, DCM then ether and dried in vacuo to give the title 
compound as an orange solid (1.2g. ftmctionality 0.23mmol/g by Fmoc loading test 
(Section 9.1)) 
fit (KBr disc) u = 3329-3430 (NH), 2840-3080 (aromatic CH and CH2), 1736, 
1720, 1701 (C=O), 1655 (C=O, amide I), 1685 (C=O, amide II), 1600cm 1 (CC). 
Dibenzoa,d1cycIoheptadien_5_one_(2_oxy_methy1poJystyrene) resin (107)23 
2-Hydroxydibenzo[a, d]cyc!oheptadien-5-one (100) (5. 0g, 22. 3mmol) was dissolved 
in 'BuOHIHO (1:1, SOmI) and cesium hydroxide (3.75g, 22mmol) was added. The 
solution was stirred for 10 minutes before the t-BuOH was removed in vacuo. The 
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cesium salt (106) was dried by azeotropic distillation with pyridine (2 x lOOmi) and 
DMF (3 x lOOml). The salt was dissolved in DMF (50m1) and added to 
chioromethylpolystyrene resin (105) (5.38g, 6mmol, 1.06mmoIIg) preswollen in DMF 
(25m1). The reaction was stirred mechanically under reflux for 4 days at 60 °C. The 
resin was filtered washed with copious DMF, i-PrOH, H20, DMIF and finally i-PrOH. 
The resin was dried in vacuo to give the title compound as an off white solid (6.48g. 
1. Ommollg). 
lit (KBr disc), Um = 3000-3100 (aromatic CH), 2840-3000 (CH2), 1638 (CO 3 
ketone), 1490, 1560 and 1596cmd  (C=C). Cl analysis, Found, <0.3%. Expected, 
4.2% for CMP resin. 
Dibenzo [a,dI cycloheptadien-5-oI-(2-oxy-methylpolystyrene) resin (108)23 
THF 	(30m1) 	was 	added 	to 	dibenzo[a,d]cycloheptadien-5-one-(2-o)cy- 
methylpolystyrene) resin (107) (0.25g. 0.62ninioi) along with LiBH4 (0.11g, 
4.9mmo!) and the mixture was heated under reflux for lh, under nitrogen, while 
stirring mechanically. The reaction mixture was filtered, washed with TIff, MeOH 
then ether and dried in vacuo to give the title compound as a white solid (0.28g). 
lit (KBr disc), Umax = 3428 (OH), 3000-3100 (aromatic CH), 2840-2980 (CH2), 1490, 
1585, 1605cn1' (C=C). 
Dibenzo[a,d]cycloheptadien-5-Boc-hydrazide-(2-oxy-methylpolystyrene) resin ( 
MP resin) (18) 23 
N-t-Butoxycarbonylhydrazine (0.18g, 1.33mmol) was dissolved in DCM (20m1) and 
added to resin (108) (0.18g, 0.22mmol) followed by benzene suiphonic acid (0.04g. 
0.22mmofl. The mixture was heated under reflux for 24h before it was filtered. The 
resin was washed with DCM. D1\4F then ether and dried in vacuo (0.23g). 
lilt (KBr disc), Um&,, = 3410 (NH), 2980-3100 (aromatic CH), 2840-2980 (CH 2), 1719 
(C=O), 1494, 1585, 1600cni' (CC). 
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Fmoc-Gly hydrazide MV resin 2 '3 
To FmocGly-OH (0.5g, 1.68mmo1) was added DCM (20m1), thionyl chloride (1.2m1, 
16.8mmol) and DMF (0.lml). The mixture was stirred for 30 minutes at which time 
all reactants had gone into solution and gas evolution had ceased. Excess thionyl 
chloride was removed in vacuo and the residue was redissolved in DCM and added to 
Boc-hydrazide-MP resin (18) preswollen in DCM (lOml) and pyridine (0.6m1). The 
mixture was heated under reflux for 6h. The resin was filtered, washed with DCM, 
DMF then ether and dried in vacua (0.3g). Functionality was shown to be 
0. 53mmoJJg by Fmoc loading test (Section 9.1) 
lIP. (KBr disc), u 	= 3421 (NH), 2966-3100 (aromatic CH), 2840-2928 (CH2), 




9-Fluorenylmethylcarbamate (prepared by the method of Carpino) (0.45g, 1.86mmol) 
was dissolved in 1,4-dioxane (30m1) and added to the resin (108) (0.25g. 0.31mmol) 
through a cotton wool filter to remove any insoluble material. Benzene suiphonic acid 
(0.05g, 0.3 lmmol) was added and the mixture was stirred (via mechanical stirrer) 
under dry nitrogen for 6h. The resin was filtered, washed with 1,4-dioxane, DMF 
then ether and dried in vacuo (0.28g, functionality of resin 0.59mmolIg by Fmoc 
loading test (Section 9.1)) 
Ut (KBr disc), u,,... = 3325-3426 (NH), 2840-3080 (aromatic CH and CL!2), 1686-
1750 (CO, urethane), 1485, 1585 and 1605cn1' (C=C). UV (20% piperidinefDMF) 
k. = 300 and 290mn. 
N"-Hopa-Cys(Acm)-Ser-Asn-Leu-Ser-Thr-Cys(Acm)-VaI-Leu-Gly-NIIINH2 
(SCT 1-10) (109) 
The initial resin was Fmoc-Gly-hydrazide CMP resin (0.47g. 0.25mmol, 0.56mmollg). 
All amino acids were coupled using the HOilt method and cysteine side chains were 
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protected with the acetomidomethyl (Acm) group. Asn was protected with lit and 
Thr and Ser were protected as stated in the notes. The completed peptide-resin was 
filtered, washed with DMF, DCM then ether and an additional capping step was 
performed manually in a sonic bath. Fmoc was removed from the resin (600mg) by 
sonication in 20% piperidine/DMF for 10 minutes. The resin was filtered and washed 
with DMF, DCM then ether. The deprotected peptide-resin (0.48g) was swollen in 
DMF (lOml) and a solution of 4-'butoxyphenylacetic acid (0.21g. Immol) with DIC 
(68p.l, 0.5mmol) in DMF (2m1) was added. The mixture was sonicated for 2h before 
the resin was filtered, washed with DMF, DCM then ether. Quantitative Kaiser test 
showed only 0.01% unreacted amine. The protected peptide-resin was stirred in EDT 
(0. 5m]), thioanisole (1. 17m1), m-cresol (0.lail) and TFA(7.5ml)for 10 minutes at 0 °C 
under nitrogen before TMSBr (1.32ml) was added. The resulting mixture was stirred 
for 45 minutes. The resin was removed by filtration and the filtrate was reduced in 
vacuo. The peptide was precipitated from ether, filtered and washed with ether. The 
crude peptide (184mg) was solubilised in 6M Gdm.HC1 and purified by HPLC (ABI 
Aquapore RP300 C8,250 x 10mm, 201A, A = H20, B = CH3CN, 0.1% TFA; 5m1/min. 
10-40 %B over 20 minutes. X = 214nm). 1t = 15 minutes, 36%B and lyophilised to 
yield the title compound as a white fluffy solid. 
Yield 90mg, 28%. 
HPLC (ABI Aquapore RP300 C8, 220 x 4.6mm, 7R.  A = H20, B = CH3CN, 0.1% 
TFA; lml/min. 10-90 %B over 30 minutes. X = 214nm). R = 17 minutes, 50 1/6B. 
MS (MALDI TOE) m/z = 1309.9 (MW, Na' salt). Amino acid analysis (24h 
hydrolysis): Asx 1 l.0, Thr 1 0.89, Ser22.2 Gly i l.l, Cys2O.4, Val 1 l.1, Leu22.0. 
ff-Lys(Hopa)-Leu-Ser-GIn-Glu-Lcu-llis-Lys(Hopa)-Leu-GIn-Thr-Tyr-Pro-Arg-
Thr-Asn-Thr-GIy-Ser-Gty-Thr-Pro-NH 2 (SCT 11-32) (111) 
The initial resin was N-9-fluorenylmethoxycarbonyl-N'-2-copoly (styrene-1%-
divinylbenzene) methoxydibeniocycloheptadien- 5 -yl amide resin (provided by 
Bachem, 0.38g, 0.25mmol, 0.65mmolIg). The amino acids were coupled using the 
HOBt method and lysine was coupled as its 4-beazy1oxypheny1acetaniidomethyl 
128 
Chapter eight: Experimental 
(Bepa) derivative which was given an extended coupling time. Gin and Asn were 
protected with lit and the remaining amino acid side-chains were protected as stated 
in the notes. The completed peptide-resin (1.3g. 0. l4mmol, 0.1 lmmollg) was 
sonicated in 20% piperidine /DMF to remove the Fmoc protecting group. The resin 
was filtered, washed with DMF, DCM then ether. Thflmoc was loaded onto the dried 
peptide-resin (1. 15g, 0. 14mmol, 0. 12mmolIg) as described previously. A Thflnoc 
loading test gave a final resin functionality of 0.08mmolIg. The peptide was cleaved 
from the resin by stirring in EDT (2m1), thioauisole (0.5m1), H 20 (0.5m1) and phenol 
(0.75g) for 10 minutes. TEA (lOmI) was then added and the resulting mixture was 
stirred in the absence of light for 5h. The cleaved resin was filtered off and washed 
with TFA (2m1). The filtrate was reduced in vacuo and the peptide was precipitated 
from ether, filtered and lyophilised to a gun]. The gum was taken into 30% 
CH3CN/H20 and adsorbed onto POC (0.8g). The PGC was washed copiously with 
30% CH3CNIH20 to remove impurities and the peptide was cleaved from Thfinoc by 
washing the PGC with 10% piperidine in 30%CH3 CN/H20. The mixture was 
separated by preparative FIPLC (ABI Aquapore RP300 C18, 250 x 10mm, 20M,  A = 
H20, B = CH3CN, 0.1% TFA; Smllmin. 10-50 %B over 20 minutes. X = 214nm). 
Three fractions were collected and lyophilised R t = 11, 14 and 17 minutes, 33, 41 and 
48%B. MS (MALDI TOF) of the three fractions showed that there was incomplete 
cleavage of the lysine protecting group from the 4-benzyloxy to the 4-
hydroxyphenylacetamide, thus fractions 2 and 3 were combined and stirred in 
cleavage mixture, as above, for 3h. The mixture was reduced in vacuo, lyophilised 
and combined with fraction 1 to give the title compound as a white fluffy solid. 
Yield 2 1.8mg, 8.7%. 
HPLC (ABI Aquapore RP300 C18, 220 x 4.6mm, 7s, A = 1120, B = C113CN, 0.1% 
TFA; lmI/min. 10-90 %B over 30 minutes. X = 214nm). R4 = 14 minutes, 42%B. 
MS (MALDI TOF) m/z = 2722.8 (MW). MS (FAB), m/z = 2726 (MW). FIRMS 
(FAB), m/z = 2725.40374 (MW, C12211 1 89N33038 Requires, 2725.39135). Amino acid 
analysis (24h hydrolysis), Asx 1 l.1, Thr43.8, Ser2 l.7, Glx33.3, Pr022.4, Tyri0.98, 
His 1 l.0, Gly22.1, Leu32.8, Lys22.I, Arg i 0.8. 
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N"-Hopa-Cys(Acm)-Ser-Asn-Leu-Ser-Thr-Cys(Acm)-Val-Leu-GIy-Lys(Hopa)-
Leu-Ser-GIn-GIu-Leu-His-Lys(Hopa)-Leu-G1n-Thr-Tyr-Pro-Arg-Thr-Asnmr-
GIy-Ser-GIy-Thr-Pro-NIH 2 (llopa-SCT1-32) (112) 
The peptide hydrazide (109) (14.1mg, 0.OImmol) was taken into DMF (3m1) and 
cooled to -20°C in an acetone/thy ice bath. 4M HC1 in 1,4-dioxane (1.03psl) was 
added and the mixture was allowed to warm to -15 °C. t-Butyl nitrite (1.6341) was 
added and the temperature was allowed to rise to - 10 °C and remained at - 10 °C for 10 
minutes to allow formation of the azide (110). A solution of the amino component 
(111) (20.8mg, 0.008mmol) in precooled DMF (imi) was added dropwise. A stock 
solution of DIEA (lOOM') in DMF (lOml) was made and an aliquot (532M1)  was 
added. The mixture was incubated at 0 °C for 24h and for the first 6h base (22p1) 
from the stock solution was added every hour. A second aliquot of azide (110) was 
added after 24h and a third after a further 24h with addition of base as above. The 
mixture remained at 0°C for 2 days. The coupling was monitored by HPLC (ABI 
Aquapore RP300 C8, 220 x 4.6mm, 7p, A = H20, B = CH3 CN, 0.1% TFA; lml/min. 
10-90 %B over 30 minutes. A. = 214nm) and was stopped after a total of 4 days 
incubation by adding AcOH (1% v/v, Imi). The mixture was reduced in vacuo to an 
oil which was taken into 6M Gdm.HC1 and purified by HPLC (ABI Aquapore RP300 
C8, 250 x 10mm, 20R  A = H20, B = CH3CN, 0.1% TFA; 5m1/min. 10-90 %B over 
60 minutes. A. = 214nm). Three fractions were isolated R = 12, 15 and 18 minutes; 
38, 44 and 53%B. Fraction I corresponded to uuireacted amine, fraction 2 
corresponded to unreacted azide and fraction 3 corresponded to the desired product 
which was lyophilised to yield the title compound as a white fluffy solid. 
Yield 6mg, 20%. 
HPLC (ABI Aquapore RP300 C8, 220 x 4.6mm, 7.t, A = 1120, B = CH3CN, 0.1% 
TFA; lmllmin. 10-90 %B over 30 minutes. A. = 214nm). lt = 21 minutes 61%B. 
MS (MALDI TOF), mlz = 3975.5. Amino acid analysis (48h hydrolysis): Asx 22. 1, 
Thr55.5, Ser44.4, G1x32.7, Pr02 1.7, 01y33.3, Cys20.15, Va122.2, Leu55.4, Tyril.0, 
HisiI.l,Lys22.4, Arg i l.3. 
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(112) (6mg, 1.5Mmol) was added to Tris.HCI (6m1, 50mM, pH8.1) and resin bound 
penicillin acylase (138mg, E.C.3.5.1.11, 1325M.units/Kg, supplied by SmithKline 
Beecham Pharmaceuticals Ltd) was added. The mixture was allowed to mix gently 
whilst incubating at 37°C. The progress of the reaction was monitored by HPLC 
(ABI Cs Aqupore RP300. 100 x 4.6, 7M  A = H20, B = CH3CN, 0.1% TM., lmllniin. 
10-90%B over 30 minutes. X = 214nm). Fresh enzyme (50mg) was added after 47h 
and the reaction was stopped after 48h by addition of AcOH., purified by analytical 
HPLC (column as above). L = 18 minutes, 55%B, l9minutes, 57%B. Fraction 2 
was partially deprotected peptide (one Hopa on) and fraction 1 corresponded to the 
title compound and was lyophilised to a white fluffy solid. 
Yield 1.5mg, 28%. 
HPLC (ABI Aquapore RP300 C8. 220 x 4.6mm, 7.t, A = H20, B = CH3CN, 0.1% 
TFA, imi/min. 10-90%B over 30 minutes. X = 214nm). R = 18 minutes, 55%B. 
MS (MALDI TOF), m/z = 3578.5 (MW). Amino acid analysis (36h hydrolysis): 
Asx2 l.9, Thr44.1, Ser43.7, G1x33.2, Pr022.0, G1y33.2, Val i l.1, Leu55.0, Tyr1 l.2, 
His 1 l.0, Lys22.2, Arg i l.l, Cys2 1.2. 
H-Ala-Gin-Lys(Tnm)-GIu-Ala-lie-Ser-Pro-Pro-Asp-Ala-Ala-OH (hEPO 114-
125) (117) 
The initial resin was Fmoc-Ala loaded Wang resin (0.5g. 0.25mmol, 0.5mmollg). All 
amino acids were coupled as their HOCt active esters, lysine was incorporated as its 
1, 5-dioxaspiro- (5,5] -undecane- 3 -nitro,  3-methoxycarbonyl (Trim) derivative and 
Fmoc was removed from the last amino acid. Gin was protected with Tit and Asp, 
Ser and Glu were protected as stated in the notes. Alter synthesis the resin was 
filtered, washed with DMF, DCM then ether and dried. The peptide was cleaved 
from the resin by first stirring in EDT (2m1), anisole (0.5m1) and H20 (0.5m1) for 10 
minutes and then after addition of TFA the mixture was stirred for 2h. The resin was 
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filtered, washed with TFA (2ml) and the filtrate was reduced in vacuo to an oil. The 
peptide was precipitated from ether, filtered and washed with ether. The peptide was 
solubilised in 10%AcOHIH20 and lyophilised to yield the title compound as a white 
fluffy solid. 
Yield 260mg, 76%. 
HPLC (Vydac C8, 250 x 2.6mm, 5.t, A = H20, B = CH3CN, 0.1% TFA; Imi/min. 
10-90 %B over 30 minutes. X = 214mn). K = 18 minutes, 56%B. MS 
(MALDITOF), mlz = 1374.66. Amino acid analysis (24h hydrolysis), Found Asx 1 l.0, 
Ser 1 0.8, G1x2 1.97, Pr0 22.4, Ala43.9, fle 1 l.0, Lys i 0.9. 
Fmoc-NH-Thr-Leu-Leu-Arg-Ala-Leu-GIy-NIINH 2 (Fmoe hEPO 107-113-
NIIINII2) (118) 
The initial resin was Fmoc-Gly hydrazide MP resin (0.55g, 0.25mmol, 0.43mmolIg). 
The amino acid side-chains were protected as stated in the notes. All amino acids 
were coupled using the HOCt method and threonine was double coupled. Fmoc was 
not removed from the last amino acid. The resin (0.63g) was cleaved by stirring in 
EDT (2m1), thioanisole (0.5m1), H 20 (0.5m1) and phenol (0.75g) for 10 minutes and 
then after the addition of TFA (lOml) for 3h. The resin was filtered, washed with 
TFA (2m1) and the filtrate was reduced in vacuo to an oil. The peptide was 
precipitated from ether, filtered and taken up into 70%CH 3CN/H20. The peptide was 
lyophilised and isolated by preparative HPLC (ABI Aquapore RP300 C8. 250 x 
10mm, 2Oji, A = H20, B = CH3CN, 0.1% TFA, Smllmin. 10-90%B over 30 minutes. 
X = 214nm). K = 17 minutes, 58%B. The purified peptide was lyophilised to yield 
the title compound as a white fluffy solid. 
Yield 98mg, 40%. 
HPLC (ABI Aquapore RP300 C8. 220 x 4.6mm, vi',  A = 1120, B = CH3CN, 0.1% 
TFA, lmllmin. 10-90%B over 30 minutes. X = 214nm). K = 26 minutes, 74%B. 
MS (MALDI TOF), m/z = 979.95. Amino acid analysis (24h hydrolysis), Thr 1 l.1, 
Gly i l.2, A1a 1 1.0, Leu32.8, Arg 1 0.95. 
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H2N-Thr-Leu-Leu-Arg-A1a-Leu-Gly-Ma-Gln-Lys-G1u-Ma-11e-Ser-1ro-Pro-Asp-
Ma-Ma-OR (hEPO 107-125) (121) 
Route A: Coupling Fmoc-hEPO 107-I13NHNH 2 (118) to hEPO 114-125 (117) via 
convertion to the azide. 
Route B: Coupling Fmoc-hEPO 107-113N1-INH2 (118) to hEPO 114-125 (117) via 
conversion to the HOCt ester. 
Route A and Route B: Fmoc-hEPO 107-113-NHNTI 2 (118) (49mg, 0.05mmol) was 
dissolved in DMIF (Imi) and the solution was cooled to -20 °C. A solution of HCI in 
1,4-dioxane (4M, 37.2p.xl, 0. lSmmol) was added and the temperature was allowed to 
rise to -15°C, t-Butyl nitrite (7.3j4 0.06mmol) was added and the mixture was left for 
10 minutes. This allows conversion to the azide (119). 
Route A: A solution of hEPO 114-125 (117) (47.5mg, 0.04mmo 1 1 in precooled DMF 
(lml) was added to the azide (119) followed by DIEA (441, 0.03mmo1). The mixture 
was allowed to warm to 0 °C and more base (18R1,  0.l3mmol) was added at a rate of 
'ipI every 0.5h. 
Route B: HOCt (0.02g. 0.45mimol) was added to the azide (119) and after 10 
minutes the temperature was allowed to rise to -10 °C. A solution of hEPO 114-125 
(117) (47.5mg, 0.04mmol) in precooled DMF (imi) was added followed by DIEA 
(29.tl, 0.45mmol) and the mixture was allowed to warm to 0°C. More base (23p.l, 
0. 13mmol) was added at a rate of 4M1  every 0.5h. 
Route A and Route B: The mixture was stored at 0 °C overnight. The product (120) 
started to precipitate from solution as the reaction proceeded. The coupling was 
monitored by HPLC (Vydac C8. 250 x 2.6mm, 5p, A = H20, B = CH3CN, 0.1% 
TF& lnillmin. 10-90%B over 30 minutes. 2L = 214nm) and was thought to be 
complete after 36h due to the disappearance of the amine component (R t = 18 
minutes, 56%B). The reaction was stopped by addition of ether from which the 
reaction mixture precicpitated. The precipitate was filtered, dissolved in 
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30%AcOHIH20 and finally lyophilised to a white fluffy solid. The crude peptide 
(120) (57.3mg, 24.7j.xmol) was dissolved in 10% piperidine/70%CH3CN/H20 to 
remove the Fmoc protecting group and simultaneously deprotect the side-chain of 
lysine. The solution was stored at room temperature overnight before acidifying with 
AcOH. The mixture was purified by preparative HPLC (ABI Aquapore RP300 C8. 
250 x 10mm, 2Ops, A = H20. B = CH3CN, 0.1% TFA, 5m1/min. 10-90%B over 30 
minutes. X = 214nm). The pure peptide was lyophilised to a white fluffy solid. 
Yield 11mg, 14.3%. 
HPLC (Vydac Cg. 250 x 2.6mm, 5R  A = 1120, B = CH3CN, 0.1% TFA, imi/min. 
10-90%B over 30 minutes. X = 214nm). R = 20 minutes, 49%B. MS (MALDI 
TOF), m/z = 1919.56 (M14). Amino acid analysis (24h hydrolysis), Asx 1 0.89, 
Thr 1 I.09, Ser1 0.67, GIx i l.Ol,Gly i 0.95, A1a54.96, Pro 1 I.08, 11e 1 0.71, Leu32.98, 
Lys i 0.9, Arg 1 0.97. 
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